id,source,title,tags,confidence,caption
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s05-01,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 5,,low,| 5 2/11/25
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s06-01,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 6,peto|bmj|cessation,low,"12/12/2023 Peto, BMJ 2000; 321:323-9. As cessation time increases, lung cancer risk decreases substantially but always higher than never smokers Lung Cancer Ris"
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s06-02,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 6,peto|bmj|cessation,low,"12/12/2023 Peto, BMJ 2000; 321:323-9. As cessation time increases, lung cancer risk decreases substantially but always higher than never smokers Lung Cancer Ris"
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s09-01,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 9,,low,
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s19-01,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 19,,low,
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s19-02,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 19,,low,
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s20-01,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 20,,low,
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s20-02,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 20,,low,
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s24-01,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 24,diagnosis|overnight|polysomnography,low,Diagnosis Overnight polysomnography Attenuated sleep studies – Home sleep tests Sleep Disordered Breathing
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s39-01,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 39,macroscopic|appearance|subpleural,low,Macroscopic Appearance Subpleural fibrosis with dilated air spaces (honeycombing) Involvement of lower lobes initially in IPF
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s39-02,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 39,macroscopic|appearance|subpleural,low,Macroscopic Appearance Subpleural fibrosis with dilated air spaces (honeycombing) Involvement of lower lobes initially in IPF
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s41-01,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 41,cellular|fibrosing|nsip,low,Cellular and fibrosing NSIP
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s48-01,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 48,silicosis|silica|reacts,low,"Silicosis Silica reacts with macrophages leading to activation and secretion of mediators, recruitment of fibroblasts and fibrosis Toxic to macrophages leading "
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s54-01,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 54,asbestosis|interstitial|fibrosis,low,Asbestosis Interstitial fibrosis which tends to involve lower lobes initially Heterogenous histology with preserved lung and areas of fibrotic lung tissue Asbes
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s55-01,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 55,asbestos|associated|pleural,low,Asbestos Associated Pleural Disease Separate lectures will cover Pleural effusions – early sign Pleural plaques Diffuse pleural fibrosis Mesotheliomas 7-10% of 
pulm-aecom-exam-2-review-2025-2-10-25-with-recording-s55-02,AECOM Exam 2 review 2025 2.10.25 with recording.pptx,AECOM Exam 2 review 2025 2.10.25 with recording Slide 55,asbestos|associated|pleural,low,Asbestos Associated Pleural Disease Separate lectures will cover Pleural effusions – early sign Pleural plaques Diffuse pleural fibrosis Mesotheliomas 7-10% of 
pulm-aecom-exam-2-review-2025-2-10-25-s06-01,AECOM Exam 2 review 2025 2.10.25.pptx,AECOM Exam 2 review 2025 2.10.25 Slide 6,peto|bmj|cessation,low,"12/12/2023 Peto, BMJ 2000; 321:323-9. As cessation time increases, lung cancer risk decreases substantially but always higher than never smokers Lung Cancer Ris"
pulm-aecom-exam-2-review-2025-2-10-25-s19-01,AECOM Exam 2 review 2025 2.10.25.pptx,AECOM Exam 2 review 2025 2.10.25 Slide 19,,low,
pulm-aecom-exam-2-review-2025-2-10-25-s20-01,AECOM Exam 2 review 2025 2.10.25.pptx,AECOM Exam 2 review 2025 2.10.25 Slide 20,,low,
pulm-aecom-exam-2-review-2025-2-10-25-s39-01,AECOM Exam 2 review 2025 2.10.25.pptx,AECOM Exam 2 review 2025 2.10.25 Slide 39,macroscopic|appearance|subpleural,low,Macroscopic Appearance Subpleural fibrosis with dilated air spaces (honeycombing) Involvement of lower lobes initially in IPF
pulm-aecom-exam-2-review-2025-2-10-25-s55-01,AECOM Exam 2 review 2025 2.10.25.pptx,AECOM Exam 2 review 2025 2.10.25 Slide 55,asbestos|associated|pleural,low,Asbestos Associated Pleural Disease Separate lectures will cover Pleural effusions – early sign Pleural plaques Diffuse pleural fibrosis Mesotheliomas 7-10% of 
pulm-aecom-sarcoidosis-ay2425-s03-01,AECOM Sarcoidosis AY2425.pptx,Case Presentation,Case Presentation|year-old|female|presents,low,A 40-year-old female presents to a pulmonologist because she had a chest x-ray for work clearance and bilateral hilar adenopathy was seen. She is in her usual s
pulm-aecom-sarcoidosis-ay2425-s19-01,AECOM Sarcoidosis AY2425.pptx,Differential Diagnoses for Noncaseating Granulomas,Differential Diagnoses for Noncaseating Granulomas|liver|granulomas|almost,low,"In liver, granulomas are almost always noncaseating In skin, noncaseating granulomas can be seen as a reaction to a foreign body (e.g. splinter) Not all granulo"
pulm-aecom-tobacco-cessation-2026-s60-01,AECOM Tobacco Cessation 2026.pptx,AECOM Tobacco Cessation 2026 Slide 60,engl|med|nejm,low,"| 60 2/3/26 n engl j med 387;4 nejm.org July 28, 2022"
pulm-l-5-diffusion-and-gas-transport-updated-1-2-2-s07-01,L 5  Diffusion and gas transport updated-1-2-2.pptx,DIFFUSION BARRIER,DIFFUSION BARRIER,low,Alveolar Space 7
pulm-l-5-diffusion-and-gas-transport-updated-1-2-2-s09-01,L 5  Diffusion and gas transport updated-1-2-2.pptx,L 5  Diffusion and gas transport updated-1-2-2 Slide 9,rest|diffusion|normal,low,Rest Diffusion Normal Abnormal Exercise Rest Normal Abnormal lung disease Grossly Abnormal Exercise 100 Diffusion at Normal PAO2 9
pulm-l-5-diffusion-and-gas-transport-updated-1-2-2-s20-01,L 5  Diffusion and gas transport updated-1-2-2.pptx,L 5  Diffusion and gas transport updated-1-2-2 Slide 20,content|dissolved|saturated,low,CONTENT = Dissolved in H2O + Saturated or Bound to Hemoglobin (Hb) Dissolved O2 Total O2 Oxyhemoglobin O2 100 75 50 25 Hb Sat % PO2 mmHg 100 O2 Content and the 
pulm-l-5-diffusion-and-gas-transport-updated-1-2-2-s23-01,L 5  Diffusion and gas transport updated-1-2-2.pptx,L 5  Diffusion and gas transport updated-1-2-2 Slide 23,total|oxyhemoglobin|sat,low,Total O2 Oxyhemoglobin O2 100 75 50 25 Hb Sat % 100 23 O2 TRANSPORT TERMS O2 content @ PO2 = 40 = Hypoxia total dissolved O2 + bound O2 ex. PO2 = 40 mm Hg; 15 g
pulm-l-5-diffusion-and-gas-transport-updated-1-2-2-s26-01,L 5  Diffusion and gas transport updated-1-2-2.pptx,L 5  Diffusion and gas transport updated-1-2-2 Slide 26,dissolved|total|oxyhemoglobin,low,Dissolved O2 Total O2 Oxyhemoglobin O2 100 110 0 75 50 25 Hb Sat % PO2 mmHg Sigmoid shape: cooperative (4 site) binding due to heme-heme interaction Flat Top Re
pulm-l-5-diffusion-and-gas-transport-updated-1-2-2-s27-01,L 5  Diffusion and gas transport updated-1-2-2.pptx,L 5  Diffusion and gas transport updated-1-2-2 Slide 27,high|tissues|tissue,low,CO2 = H+ high at tissues Tissue pH (7.38) lower than lung pH (7.41) Desirable for low pH to lower HbO2 affinity thereby favoring unloading of O2 at the tissues 
pulm-l-5-diffusion-and-gas-transport-updated-1-2-2-s28-01,L 5  Diffusion and gas transport updated-1-2-2.pptx,L 5  Diffusion and gas transport updated-1-2-2 Slide 28,produced|highest|tissues,low,CO2 = H+ Produced & highest at tissues Tissue CO2 higher than lung CO2 Desirable for high CO2 to decrease HbO2 affinity at the tissues Favors O2 unloading at th
pulm-l-5-diffusion-and-gas-transport-updated-1-2-2-s30-01,L 5  Diffusion and gas transport updated-1-2-2.pptx,L 5  Diffusion and gas transport updated-1-2-2 Slide 30,dpg|increases|hbo,low,"As 2,3–DPG increases HbO2 affinity Decreases P50 Increases right shift Favors O2 unloading at the tissues 2,3—DPG increases P50 increases Right Shift HbO2 2,3-D"
pulm-l-5-diffusion-and-gas-transport-updated-1-2-2-s31-01,L 5  Diffusion and gas transport updated-1-2-2.pptx,L 5  Diffusion and gas transport updated-1-2-2 Slide 31,temp|increase|lowers,low,Temp Increase: lowers affinity right shift increase P50 Favors O2 unloading at the tissues ~5% shift / 10C synergistic with H+ Ex. sepsis Temp increases: P50 in
pulm-l-5-diffusion-and-gas-transport-updated-1-2-2-s32-01,L 5  Diffusion and gas transport updated-1-2-2.pptx,L 5  Diffusion and gas transport updated-1-2-2 Slide 32,right|shift|higher,low,"Right shift or Higher P50 in illness due to High: Temperature 2,3-DPG (in low O2) PaCO2 H+ or Acid pH Left shift or Lower P50 PaO2 mmHg Hb sat (%) HbO2 Dissocia"
pulm-l-5-diffusion-and-gas-transport-updated-1-2-2-s33-01,L 5  Diffusion and gas transport updated-1-2-2.pptx,L 5  Diffusion and gas transport updated-1-2-2 Slide 33,fetal|adult|hbo,low,Fetal vs. Adult HbO2 Dissociation Curve 33 PaO2 mmHg
pulm-l-5-diffusion-and-gas-transport-updated-1-2-2-s34-01,L 5  Diffusion and gas transport updated-1-2-2.pptx,L 5  Diffusion and gas transport updated-1-2-2 Slide 34,hbco|hbo|binds,low,HbCO > HbO2 CO binds more readily to Hb than does O2 CO lowers actual HbO2 sat. decreasing O2 transport Normal (0 % CO) 50 % CO PaO2 mmHg Hb-O2 bound CO looks l
pulm-l-5-diffusion-and-gas-transport-updated-1-2-2-s43-01,L 5  Diffusion and gas transport updated-1-2-2.pptx,L 5  Diffusion and gas transport updated-1-2-2 Slide 43,red|blood|cell,low,In red blood cell CO2 -->H+ + HCO3 - carbonic anhydrase H+ buffering carbamino cpds HbO2 ->Hb->HbH+ HCO3 - cell --> plasma electric neutral chloride pump In Per
pulm-l-5-diffusion-and-gas-transport-updated-1-2-2-s44-01,L 5  Diffusion and gas transport updated-1-2-2.pptx,L 5  Diffusion and gas transport updated-1-2-2 Slide 44,oxygenation|hbh|hbo,low,Hb Oxygenation HbH+->HbO2 + H+ In cell H+ + HCO3--> CO2 carbonic anhydrase CO2 excreted HCO3- plasma --> cell electric neutral chloride pump In the Lung Chlorid
pulm-l-6-vq-mismatch-updated-v2-s05-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 5,right|heart|deoxygenated,low,5 Right Heart Deoxygenated blood “Venous blood” Left Heart Oxygenated blood Systemic Circulation Arterial blood Bronchial circulation Oxygenated blood Circulati
pulm-l-6-vq-mismatch-updated-v2-s16-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 16,exercise|rest|sitting,low,Exercise Rest Sitting Supine Max Inspiration Distance Up Lung (cm) Top GRAVITATIONAL GRADIENT 16 Bottom
pulm-l-6-vq-mismatch-updated-v2-s17-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 17,zone|waterfall|distention,low,Zone 3 Zone 2 Zone 1 PA > Pa Zone 4 Waterfall Distention Collapse Blood Flow Zone 1 Hydrostatic gravitational forces cause: P arterial (Pa) to be too low at top
pulm-l-6-vq-mismatch-updated-v2-s18-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 18,zone|waterfall|distention,low,Zone 3 Zone 2 Pa > PA > Pv Zone 1 Zone 4 Waterfall Distention Collapse Blood Flow Zone 2 Hydrostatic gravitational forces cause: P arterial (Pa) to rise in mid-
pulm-l-6-vq-mismatch-updated-v2-s19-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 19,zone|waterfall|distention,low,Zone 3 Pa > Pv > PA Zone 2 Zone 1 Zone 4 Waterfall Distention Collapse Blood Flow Zone 3 Hydrostatic gravitational forces cause: P arterial (Pa) & P venous (Pv)
pulm-l-6-vq-mismatch-updated-v2-s24-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 24,increases|total|mismatch,low,Increases in total V/Q mismatch For most diseases increase in total V/Q mismatch is more low than high V/Q As V/Q mismatch increases PaCO2 rises & PaO2 falls So
pulm-l-6-vq-mismatch-updated-v2-s25-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 25,pao|lot|mismatch,low,PaO2 A lot of Mismatch V/Q=1 No Mismatch Amount of Mismatched V/Q (low>>high) At A Given Alveolar Ventilation VA 25 ---- Compensatory Increased VA PaCO2 PaO2 Pa
pulm-l-6-vq-mismatch-updated-v2-s26-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 26,diseases|effect|ventilation,low,"Most Diseases effect ventilation more than perfusion leading to: Increase Low V/Q alveoli: PCO2 rises, PO2 falls In response, brain signals for VA to increase r"
pulm-l-6-vq-mismatch-updated-v2-s30-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 30,dissolved|total|oxyhemoglobin,low,Dissolved O2 Total O2 Oxyhemoglobin O2 100 75 50 25 Hb Sat % PO2 mmHg 100 30 O2 Content = dissolved + saturated O2 dissolved is minimal HbO2 sat or O2 bound is 
pulm-l-6-vq-mismatch-updated-v2-s34-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 34,content|saturated|dissolved,low,O2 content = saturated + dissolved Content = O2 saturated + O2 dissolved Normal Hemoglobin = 15 g Hb / 100 ml blood (O2 sat x 1.34 ml O2/g Hb x 15g Hb) + (0.003
pulm-l-6-vq-mismatch-updated-v2-s35-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 35,pao|sat|content,low,"For PaO2 of 110 (O2 sat = 100%) O2 content = (1x1.34x15) + (.003 x 110) = 20.1+0.33 = 20.43 ml O2 / 100 ml blood O2 Content for PO2 110, 90 and 130 35 For PaO2 "
pulm-l-6-vq-mismatch-updated-v2-s36-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 36,pao|sat|content,low,"For PaO2 of 110 (O2 sat = 100%) O2 content = (1x1.34x15) + (.003 x 110) = 20.1+0.33 = 20.43 ml O2 / 100 ml blood O2 Content for PO2 110, 90 and 130 36 For PaO2 "
pulm-l-6-vq-mismatch-updated-v2-s37-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 37,pco|capillary|equilibrium,low,PcO2 = P capillary O2 in equilibrium with PAO2 Assume Equal perfusion to Each of 3 Areas O2 content = [(20.1+0.33) + (19.09+0.27) + (20.1+0.39)] / 3 = O2 conten
pulm-l-6-vq-mismatch-updated-v2-s38-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 38,pco|capillary|equilibrium,low,PcO2 = P capillary O2 in equilibrium with PAO2 Assume Equal perfusion to Each of 3 Areas O2 content = [(20.1+0.33) + (19.09+0.27) + (20.1+0.39)] / 3 = O2 conten
pulm-l-6-vq-mismatch-updated-v2-s40-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 40,fio|pao|high,low,FIO2 PaO2 High V/Q 10 1.0 0.01 0.001 For a given FIO2: 10 x increase V/Q (ex. 1 to 10) minor increase PaO2 and O2 content Why? Because HbO2 already at max satur
pulm-l-6-vq-mismatch-updated-v2-s41-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 41,low|units|hbo,low,"But in low V/Q units, HbO2 saturation is NOT 100% (ex. 0.1 vs 1) major decrease in O2 content which can be improved with supplemental O2 FIO2 PaO2 High V/Q 10 1"
pulm-l-6-vq-mismatch-updated-v2-s43-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 43,pao|sat|content,low,"For PaO2 of 673 (O2 sat = 100%) O2 content = (1x1.34x15) + (.003 x 673) = 20.1 + 2.02 = 22.12 ml O2 / 100 ml blood O2 Content for PO2 673, 653 and 693 43 For Pa"
pulm-l-6-vq-mismatch-updated-v2-s44-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 44,right|heart|left,low,Right Heart Left Heart PvO2 = 40 PvCO2 = 46 PAO2 = 673; PACO2 = 40 PAO2 = 653; PACO2 = 60 1/3 Q -> Low V/Q 1/3 Q-> High V/Q PAO2 =693; PACO2 = 20 All of the abo
pulm-l-6-vq-mismatch-updated-v2-s45-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 45,right|heart|left,low,Right Heart Left Heart PvO2 = 40 PvCO2 = 46 PAO2 = 673; PACO2 = 40 PAO2 = 653; PACO2 = 60 1/3 Q -> Low V/Q 1/3 Q-> High V/Q PAO2 =693; PACO2 = 20 All of the abo
pulm-l-6-vq-mismatch-updated-v2-s46-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 46,mismatch|high|fio,low,If V/Q mismatch > 1.0 High FIO2 (100%) Hb already fully saturated Minimal increase PaO2 FIO2 PaO2 10 1.0 0.1 0.01 0.001 46 FIO2 and V/Q Mismatch High V/Q
pulm-l-6-vq-mismatch-updated-v2-s47-01,L 6 VQ Mismatch updated v2 .pptx,L 6 VQ Mismatch updated v2  Slide 47,fio|pao|mismatch,low,FIO2 PaO2 10 1.0 0.1 0.01 0.001 If V/Q mismatch < 1.0 Hb not fully saturated 100% FIO2 completely eliminates any impact on PaO2 from V/Q mismatch 47 High V/Q Lo
pulm-l-7-hypoxia-shunt-and-the-aa-gradient-s05-01,"L 7 Hypoxia, Shunt and the Aa gradient .pptx","L 7 Hypoxia, Shunt and the Aa gradient  Slide 5",fio|pao|mismatch,low,FIO2 PaO2 10 1.0 0.1 0.01 0.001 If V/Q mismatch < 1.0 Hb not fully saturated 100% FIO2 completely eliminates any impact on PaO2 from V/Q mismatch 5 High V/Q Low
pulm-l-7-hypoxia-shunt-and-the-aa-gradient-s07-01,"L 7 Hypoxia, Shunt and the Aa gradient .pptx","L 7 Hypoxia, Shunt and the Aa gradient  Slide 7",pao|sat|content,low,"For PaO2 of 673 (O2 sat = 100%) O2 content = (1x1.34x15) + (.003 x 673) = 20.1 + 2.02 = 22.12 ml O2 / 100 ml blood O2 Content for PO2 673, 653 and 693 7 For PaO"
pulm-l-7-hypoxia-shunt-and-the-aa-gradient-s08-01,"L 7 Hypoxia, Shunt and the Aa gradient .pptx","L 7 Hypoxia, Shunt and the Aa gradient  Slide 8",right|heart|left,low,Right Heart Left Heart PvO2 = 40 PvCO2 = 46 PAO2 = 673; PACO2 = 40 PAO2 = 653; PACO2 = 60 1/3 Q -> Low V/Q 1/3 Q-> High V/Q PAO2 =693; PACO2 = 20 All of the abo
pulm-l-7-hypoxia-shunt-and-the-aa-gradient-s09-01,"L 7 Hypoxia, Shunt and the Aa gradient .pptx","L 7 Hypoxia, Shunt and the Aa gradient  Slide 9",right|heart|left,low,Right Heart Left Heart PvO2 = 40 PvCO2 = 46 PAO2 = 673; PACO2 = 40 PAO2 = 653; PACO2 = 60 1/3 Q -> Low V/Q 1/3 Q-> High V/Q PAO2 =693; PACO2 = 20 All of the abo
pulm-l-7-hypoxia-shunt-and-the-aa-gradient-s10-01,"L 7 Hypoxia, Shunt and the Aa gradient .pptx","L 7 Hypoxia, Shunt and the Aa gradient  Slide 10",right|heart|left,low,Right Heart Left Heart PvO2 = 40 PvCO2 = 46 R=1.0 PAO2 = 673; PACO2 = 40 PAO2 = 653; PACO2 = 60 PAO2 = 40; PACO2 = 46 1/3 Q -> true Shunt V/Q=0 Assumes Equal pe
pulm-l10-11-pulmonary-function-testing-2025-3-s06-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 6,time|sec|volume,low,Time (sec) Volume (liters) FVC FEV-3 FEV1 FEV-0.5 Spirometry - Volume per Second = Flow 6
pulm-l10-11-pulmonary-function-testing-2025-3-s23-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 23,spirometry|fdny|impact,low,23 Spirometry at FDNY: Impact of Race-based predictive equations Figure 2. Difference in FEV1 % predicted (GLI-Global minus NHANES-III) by NHANES-III FEV1 % pre
pulm-l10-11-pulmonary-function-testing-2025-3-s33-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 33,lung|volumes|capacities,low,Lung Volumes & Capacities FRC RV TLC Residual Volume Functional Residual Capacity Inspiratory Reserve Volume Inspiratory Capacity Total Lung Capacity Expiratory
pulm-l10-11-pulmonary-function-testing-2025-3-s37-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 37,diffusion|dlco|emphysema,low,Diffusion (DLCO) vs Emphysema Grade DLCO Single Breath DLCO Within Breath Emphysema Grade by Tissue Pathology or CT DLCO (% predicted) DLCO when measured correc
pulm-l10-11-pulmonary-function-testing-2025-3-s38-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 38,lung|volumes|disease,low,Lung Volumes - Disease Effect IRV IRV IRV RV RV ERV ERV ERV RV TV TV TV TLC TLC TLC FRC FRC FRC VC VC VC IC IC IC Normal Restrictive Obstructive 38
pulm-l10-11-pulmonary-function-testing-2025-3-s46-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 46,,low,46
pulm-l10-11-pulmonary-function-testing-2025-3-s47-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 47,,low,47
pulm-l10-11-pulmonary-function-testing-2025-3-s48-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 48,,low,48
pulm-l10-11-pulmonary-function-testing-2025-3-s49-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 49,,low,49
pulm-l10-11-pulmonary-function-testing-2025-3-s50-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 50,,low,50
pulm-l10-11-pulmonary-function-testing-2025-3-s51-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 51,obstructivexxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx|peak|pressure,low,Obstructivexxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx Peak Pressure: Force needed to overcome Impedance Resistance +Co
pulm-l10-11-pulmonary-function-testing-2025-3-s52-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 52,obstructivexxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx|peak|pressure,low,Obstructivexxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx Peak Pressure Static Pressure x Normal Intubated Subject 52 WORK
pulm-l10-11-pulmonary-function-testing-2025-3-s53-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 53,normal|obstructive|static,low,Normal Obstructive Static Pressure Peak Pressure Peak Pressure Static Pressure WORK of BREATHING: Mechanical Ventilation 53 Resistance = Pressure / flow (Peak –
pulm-l10-11-pulmonary-function-testing-2025-3-s75-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 75,,low,75
pulm-l10-11-pulmonary-function-testing-2025-3-s76-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 76,,low,76
pulm-l10-11-pulmonary-function-testing-2025-3-s77-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 77,,low,77
pulm-l10-11-pulmonary-function-testing-2025-3-s78-01,L10 & 11 Pulmonary Function Testing 2025(3).pptx,L10 & 11 Pulmonary Function Testing 2025(3) Slide 78,,low,78
pulm-l1b-functional-anatomy-updated-1-s08-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 8,min|paco|chemosensitivity,low,VA (l/min) PACO2 Chemosensitivity Alveolar ventilation inversely related to PaCO2 40 8 FUNCTIONAL ANATOMY
pulm-l1b-functional-anatomy-updated-1-s09-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 9,respiratory|drive|synergy,low,Respiratory Drive: Synergy between hypoxia and hypercarbia As PaCO2 increases message sent to increase ventilation More rapid rise in ventilation at PaO2 < 60mm
pulm-l1b-functional-anatomy-updated-1-s10-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 10,respiratory|muscles|inspiration,low,Respiratory Muscles Inspiration Anterior Posterior Diaphragm Principal Muscle for Inspiration Diaphragm Phrenic Nerves (C3-C5) Contraction descends into abd enl
pulm-l1b-functional-anatomy-updated-1-s11-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 11,respiratory|muscles|expiratory,low,Respiratory Muscles Expiratory Assist ex. COUGH Sternocleido- Accessory Muscles For Inspiration External Intercostals For Inspiration Anterior Posterior Diaphra
pulm-l1b-functional-anatomy-updated-1-s12-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 12,trachea|rul|rml,low,Trachea RUL RML RLL L lingula LUL LLL RML L lingula 12
pulm-l1b-functional-anatomy-updated-1-s13-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 13,aaaaaa|rul|lul,low,aaaaaa RUL LUL RML RLL LLL L lingula Trachea R main L main 13
pulm-l1b-functional-anatomy-updated-1-s14-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 14,right|mainstem|bronchus,low,"14 RIGHT MAINSTEM BRONCHUS: angle is straighter than on the left side. Along with gravity, this favors right lung intubation and right lower lung aspiration"
pulm-l1b-functional-anatomy-updated-1-s14-02,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 14,right|mainstem|bronchus,low,"14 RIGHT MAINSTEM BRONCHUS: angle is straighter than on the left side. Along with gravity, this favors right lung intubation and right lower lung aspiration"
pulm-l1b-functional-anatomy-updated-1-s16-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 16,trachea|bronchi|bronchioles,low,Trachea Bronchi Bronchioles Terminal Bronchioles Respiratory Bronchioles Alveolar ducts Alveolar sacs 16
pulm-l1b-functional-anatomy-updated-1-s18-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 18,cross|sectional|area,low,Cross Sectional Area Bronchi Generation 18
pulm-l1b-functional-anatomy-updated-1-s19-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 19,airway|bronchial|generation,low,Airway (Bronchial) Generation Airway Resistance Segmental bronchi Terminal bronchioles 19
pulm-l1b-functional-anatomy-updated-1-s21-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 21,bronchus|bronchiole|mucosa,low,Bronchus Bronchiole Mucosa Submucosa Fibro-Cartilaginous Layer 21
pulm-l1b-functional-anatomy-updated-1-s25-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 25,alveolar|space|ventilatory,low,Alveolar Space Ventilatory Function Gas Exchange at the Alveolar-Capillary - Blood Interface Distance for Diffusion of Gases: Pneumocyte  Basement Membrane  V
pulm-l1b-functional-anatomy-updated-1-s26-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 26,smaller|alveoli|harder,low,"Smaller alveoli (R1): Harder to inflate; Easier deflate P = 2T / R; R1 < R2; P1 > P2 Surfactant lines inner alveolar wall WHY, Because small alveoli want to col"
pulm-l1b-functional-anatomy-updated-1-s28-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 28,saline|even|surfactant,low,Saline or even more so with Surfactant Inflation /Deflation Pressure – cm H2O HYSTERESIS 28
pulm-l1b-functional-anatomy-updated-1-s31-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 31,time|sec|rest,low,Time (sec) Rest 31 2. Abnormal 3. Grossly Abnormal Exercise Alveolar PAO2 Normal Lung Structure
pulm-l1b-functional-anatomy-updated-1-s33-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 33,vein|high|low,low,Vein High O2 Vein Low O2 Artery Low O2 Capillary Capillary 25/0 RV --------- RA 2 ~12 ~8 30 10 20 25/8 120/80 120/0 LV -------- LA 5 Artery High O2 33 PULMONARY
pulm-l1b-functional-anatomy-updated-1-s34-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 34,,low,34
pulm-l1b-functional-anatomy-updated-1-s38-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 38,mmhg|pvr|hypoxia,low,PO2 (mmHg) pH 7.1 7.2 7.3 7.4 PVR Hypoxia & Acidosis: Pulmonary vascular resistance (PVR) increases due to synergistic vasoconstriction. Opposite of Systemic va
pulm-l1b-functional-anatomy-updated-1-s39-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 39,increasing|lung|volume,low,"Increasing Lung Volume ---- FRC TLC RV Total Alveolar Extra-Alveolar PVR Lung Volume: As migrate from mid-lung volume (FRC), in either direction, PVR increases"
pulm-l1b-functional-anatomy-updated-1-s41-01,L1B. functional anatomy updated(1).pptx,L1B. functional anatomy updated(1) Slide 41,vasoconstriction|nitric|oxide,low,Vasoconstriction Nitric Oxide Vasodilation Endothelin-1 41
pulm-l2-compliance-and-volumes-updated-s09-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 9,gradient|flow|palv,low,NO GRADIENT; NO FLOW Palv = P atm Respiratory Cycle @ End Expiration 9
pulm-l2-compliance-and-volumes-updated-s11-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 11,air|flow|gradient,low,AIR FLOW Gradient; Inspiratory Flow Palv < P atm Respiratory Cycle During Inspiration Ppl < Palv < Patm 11
pulm-l2-compliance-and-volumes-updated-s12-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 12,gradient|flow|palv,low,NO GRADIENT; NO FLOW No Gradient; No Flow Palv = P atm Respiratory Cycle @ End Inspiration Ppl is negative and < Palv 12
pulm-l2-compliance-and-volumes-updated-s14-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 14,air|flow|respiratory,low,AIR FLOW Respiratory Cycle During Expiration Gradient; Expiratory Flow Palv > P atm 14
pulm-l2-compliance-and-volumes-updated-s15-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 15,smaller|alveoli|harder,low,Smaller alveoli (R1): Harder to inflate; Easier deflate P = 2T / R; R1 < R2; P1 > P2 Larger alveoli P=2T/R R=2; P=T Smaller alveoli P=2T/R R=1; P=2T COMPLIANCE 
pulm-l2-compliance-and-volumes-updated-s16-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 16,smaller|alveoli|harder,low,Smaller alveoli (R1): Harder to inflate; Easier deflate P = 2T / R; R1 < R2; P1 > P2 Larger alveoli P=2T/R R=2; P=T Smaller alveoli P=2T/R R=1; P=2T Elastic pro
pulm-l2-compliance-and-volumes-updated-s18-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 18,air|inflation|deflation,low,Air Inflation Deflation Saline or even more so with Surfactant Inflation /Deflation Pressure (cm H2O) HYSTERESIS 18
pulm-l2-compliance-and-volumes-updated-s27-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 27,frc|lung|chest,low,FRC Lung RV Chest Wall TLC Pressure (cm H2O) Mechanical Ventilation -> Positive Pressure (cm H2O) Respiratory System 27 Let’s dissect each of these 3 curves sep
pulm-l2-compliance-and-volumes-updated-s28-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 28,frc|chest|wall,low,FRC Chest Wall Lung Resp System Chest Wall P Lung P Resp Sys P A B C 28
pulm-l2-compliance-and-volumes-updated-s29-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 29,frc|chest|wall,low,FRC Chest Wall Lung Resp System Chest Wall P Lung P Resp Sys P A B C 29
pulm-l2-compliance-and-volumes-updated-s30-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 30,frc|chest|wall,low,FRC Chest Wall Lung Resp System Chest Wall P Lung P Resp Sys P A B C VC no work Zero pressure 30
pulm-l2-compliance-and-volumes-updated-s31-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 31,frc|lung|respiratory,low,FRC Lung Respiratory System RV Chest Wall TLC Pressure (cm H2O) Mechanical Ventilation -> Positive Pressure (cm H2O) 31
pulm-l2-compliance-and-volumes-updated-s33-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 33,lung|capacities|sum,low,Lung Capacities = sum of several lung volumes FRC RV TLC Residual Volume Functional Residual Capacity Inspiratory Reserve Volume Inspiratory Capacity Total Lung
pulm-l2-compliance-and-volumes-updated-s34-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 34,lung|capacities|sum,low,Lung Capacities = sum of several lung volumes FRC RV TLC Residual Volume Functional Residual Capacity Inspiratory Reserve Volume Inspiratory Capacity Total Lung
pulm-l2-compliance-and-volumes-updated-s35-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 35,lung|capacities|sum,low,Lung Capacities = sum of several lung volumes FRC RV TLC Residual Volume Functional Residual Capacity Inspiratory Reserve Volume Total Lung Capacity Expiratory 
pulm-l2-compliance-and-volumes-updated-s36-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 36,lung|capacities|sum,low,Lung Capacities = sum of several lung volumes FRC RV TLC Residual Volume Functional Residual Capacity Inspiratory Reserve Volume Inspiratory Capacity Total Lung
pulm-l2-compliance-and-volumes-updated-s37-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 37,lung|volumes|capacities,low,Lung Volumes & Capacities FRC RV TLC Residual Volume Functional Residual Capacity Inspiratory Reserve Volume Inspiratory Capacity Total Lung Capacity Expiratory
pulm-l2-compliance-and-volumes-updated-s43-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 43,compliance|frc|tlc,low,Compliance = V/P FRC + TV RV TLC Transpulmonary Pressure (cm H2O) Respiratory Normal 700 ml; 4 cm C = 175 ml/cm Compliance = ∆V/ ∆ P 43
pulm-l2-compliance-and-volumes-updated-s44-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 44,compliance|decreases|hyperinflation,low,Compliance Decreases with Hyperinflation RV TLC Transpulmonary Pressure (cm H2O) Respiratory 700 ml; 4 cm C = 175 Hyperinflated 700 ml; 10 cm C = 70 FRC + TV Co
pulm-l2-compliance-and-volumes-updated-s45-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 45,lung|transpulmonary|pressure,low,Lung Transpulmonary Pressure (cm H2O) Compliance and Disease Models Normal Inflation Overinflation -> higher Pressure Higher work of breathing 45
pulm-l2-compliance-and-volumes-updated-s46-01,L2 Compliance and volumes updated .pptx,L2 Compliance and volumes updated  Slide 46,lung|volumes|disease,low,Lung Volumes - Disease Models IRV IRV IRV RV RV ERV ERV ERV RV TV TV TV TLC TLC TLC FRC FRC FRC VC VC IC IC IC Normal Restrictive Obstructive VC 46
pulm-l3-airway-resistance-dynamic-compliance-updated-s10-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,FLOW PATTERNS,FLOW PATTERNS,low,Turbulent Laminar Transitional Vvvvvvvvvvvvvvvvvv vvvvv Laminar Flow Pattern Organized flow Small airways Turbulent Flow Pattern Disorganized flow Large airways
pulm-l3-airway-resistance-dynamic-compliance-updated-s14-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 14,cross|sectional|area,low,Cross Sectional Area Bronchi Generation 14
pulm-l3-airway-resistance-dynamic-compliance-updated-s15-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 15,airway|bronchial|generation,low,Airway (Bronchial) Generation Airway Resistance Segmental bronchi Terminal bronchioles 15
pulm-l3-airway-resistance-dynamic-compliance-updated-s16-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 16,low|density|gas,low,Low Density Gas (Helium) & Flow Rates Low Density Helium Decreases Turbulence: Increases flow rates in large but not small airways Asthma is a small airways dis
pulm-l3-airway-resistance-dynamic-compliance-updated-s18-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 18,isovolume|pressure|curves,low,"ISOVOLUME PRESSURE CURVES Expiration: For a given intra-pleural pressure as lung volume decreases, compression decreases airway radius, increases airway resista"
pulm-l3-airway-resistance-dynamic-compliance-updated-s19-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,AIRWAYS RESISTANCE,AIRWAYS RESISTANCE,low,"Expiration: For a given lung volume (in low to normal range), Higher Pressure does not increase expiratory flow. WHY FLOW LIMITED? Equal Pressure Point (EPP) 19"
pulm-l3-airway-resistance-dynamic-compliance-updated-s24-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 24,compliance|decreases|hyperinflation,low,Compliance Decreases with Hyperinflation RV TLC Transpulmonary Pressure (cm H2O) Respiratory 700 ml; 4 cm C = 175 Compliance = ∆V/ ∆ P 24 FRC + TV
pulm-l3-airway-resistance-dynamic-compliance-updated-s25-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 25,compliance|decreases|hyperinflation,low,Compliance Decreases with Hyperinflation RV TLC Transpulmonary Pressure (cm H2O) Respiratory 700 ml; 4 cm C = 175 Hyperinflated 700 ml; 10 cm C = 70 FRC + TV Co
pulm-l3-airway-resistance-dynamic-compliance-updated-s37-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 37,normals|asthmatics|respiratory,low,Normals Asthmatics Respiratory Frequency (breaths/min) Dynamic Compliance & Airway Resistance TC = R x C Normal = 5 x 100 = 500 Asthma=40 x 100=4000 Hyperinflat
pulm-l3-airway-resistance-dynamic-compliance-updated-s38-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 38,lung|volume|increases,low,Lung Volume Increases ---- FRC TLC RV Total Alveolar Extra-Alveolar Hyperinflation: Increases Pulm. Vascular Resistance & Deadspace Decreases Gas Exchange Hype
pulm-l3-airway-resistance-dynamic-compliance-updated-s39-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 39,compliance|disease|models,low,39 Compliance and Disease Models: Obstruction Due to Emphysema vs Asthma Lung Transpulmonary Pressure (cm H2O) : May also occur in normal lung tissue due to hyp
pulm-l3-airway-resistance-dynamic-compliance-updated-s41-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 41,COPD|work|breathing|busy,low,"Work of Breathing This is a busy figure. Let’s zoom in and study each panel separately. First, lets look at normal subjects on the top panel. NEXT SLIDE Normal "
pulm-l3-airway-resistance-dynamic-compliance-updated-s42-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 42,COPD|normal|copd|work,low,Normal COPD Work of Breathing in Normals: Top Panel ABC: static inflation-deflation curve OABCD: elastic work (compliance) AECF: resistive work AECB: resistive 
pulm-l3-airway-resistance-dynamic-compliance-updated-s43-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 43,COPD|work|breathing|restrictive,low,Work of Breathing in Restrictive Diseases. Next Middle Panel Normal Restrictive COPD ABC: static inflation-deflation curve OABCD: elastic work increased due to 
pulm-l3-airway-resistance-dynamic-compliance-updated-s44-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 44,COPD|normal|restrictive|copd,low,Normal Restrictive COPD ABC: static inflation-deflation curve AECF: resistive work AECB: resistive work during Inspiration 44 Work of Breathing in Obstructive D
pulm-l3-airway-resistance-dynamic-compliance-updated-s45-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 45,work|breathing|obstructive,low,Work of Breathing in Obstructive Diseases (OAD) Bottom Panel Normal Restrictive OAD ABC: static inflation-deflation curve AECF: resistive work AECB: resistive w
pulm-l3-airway-resistance-dynamic-compliance-updated-s46-01,L3 Airway Resistance _ dynamic compliance_updated.pptx,L3 Airway Resistance _ dynamic compliance_updated Slide 46,COPD|normal|restrictive|copd,low,Normal Restrictive COPD ABCF: resistive work during Expiration 46 ABCF: NOTE that the resistive work during Expiration NO LONGER is within the stored elastic re
pulm-l4-alveolar-ventilation-updated-s18-01,L4 Alveolar Ventilation updated.pptx,L4 Alveolar Ventilation updated Slide 18,normal|peco|phase,low,18 Normal PECO2 = 25 - 37 mm Hg phase phase phase IV CO2 CO2 CO2 CO2 CO2 Start here
pulm-l4-alveolar-ventilation-updated-s21-01,L4 Alveolar Ventilation updated.pptx,L4 Alveolar Ventilation updated Slide 21,chemosensitivity|constant|production,low,"VA and CHEMOSENSITIVITY For a constant CO2 production (VCO2) VA is inversely related to PaCO2 Lower VA -> higher PaCO2 At low VA (< 5 L/min), PaCO2 rises rapidl"
pulm-l4-alveolar-ventilation-updated-s25-01,L4 Alveolar Ventilation updated.pptx,L4 Alveolar Ventilation updated Slide 25,rapid|rise|pao,low,"More rapid rise in VE & VA at PaO2 < 60 Synergy between hypoxia and hypercarbia: for same PaO2 , greater rise in ventilation as PaCO2 rises CHEMOSENSITIVITY, RE"
pulm-l4-alveolar-ventilation-updated-s33-01,L4 Alveolar Ventilation updated.pptx,L4 Alveolar Ventilation updated Slide 33,two|ways|think,low,Two ways to think about Work of Breathing 1. Work of breathing (WOB) = Force x Distance Requires distance (volume) change How Does Hyperinflation Affect the Wor
pulm-l4-alveolar-ventilation-updated-s34-01,L4 Alveolar Ventilation updated.pptx,L4 Alveolar Ventilation updated Slide 34,work|oxygen|consumption,low,2. Work = Oxygen Consumption Rather than force x distance If the push or struggle results in NO movement has oxygen consumption occurred? YES Work of Breathing 
pulm-l4-alveolar-ventilation-updated-s35-01,L4 Alveolar Ventilation updated.pptx,L4 Alveolar Ventilation updated Slide 35,hyperinflation|air|trapping,low,Hyperinflation = Air Trapping FRC Lung Volume Insp. Exp. Airway Obstruction with Progressive Dynamic Hyperinflation Asthma attack During Asthma Attack -> rapid 
pulm-l4-alveolar-ventilation-updated-s36-01,L4 Alveolar Ventilation updated.pptx,L4 Alveolar Ventilation updated Slide 36,work|breathing|obstructive,low,Work of Breathing in Obstructive Diseases Hyperinflation: PEEPi or Auto-PEEP No inspiratory flow until Inspiratory Pressure is negative relative to atmospheric 
pulm-l4-alveolar-ventilation-updated-s37-01,L4 Alveolar Ventilation updated.pptx,L4 Alveolar Ventilation updated Slide 37,obstructive|airways|disease,low,Obstructive Airways Disease If we define WOB by VO2 then we do not require a volume (distance) change Dynamic Hyperinflation (air-trapping) Tidal Volume migrate
pulm-l4-alveolar-ventilation-updated-s40-01,L4 Alveolar Ventilation updated.pptx,L4 Alveolar Ventilation updated Slide 40,hyperinflation|treatment|frc,low,Hyperinflation & its Treatment: FRC Lung Volume Insp. Exp. Airway Obstruction with Progressive Dynamic Hyperinflation Reduce Hyperinflation: By lowering airways
pulm-l4-alveolar-ventilation-updated-s41-01,L4 Alveolar Ventilation updated.pptx,L4 Alveolar Ventilation updated Slide 41,relative|atmospheric|pressure,low,"Relative to atmospheric pressure, intrathoracic pressure becomes negative during spontaneous inspiration Pressure surrounding abdominal vasculature remains at A"
pulm-l4-alveolar-ventilation-updated-s45-01,L4 Alveolar Ventilation updated.pptx,L4 Alveolar Ventilation updated Slide 45,summary|hyperinflation|tidal,low,Summary on Hyperinflation: For same tidal volume Over-distended balloons have Decreased compliance Greater distension pressure required at high volumes Auto-PEE
pulm-l8-wob-resp-pump-resp-failure-updated-s09-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 9,paco|increases|decreases,low,As PaCO2 increases (pH decreases) & message sent to increase ventilation More rapid rise in ventilation at PaO2 < 60 mm Hg Synergy between low PO2 (hypoxia) and
pulm-l8-wob-resp-pump-resp-failure-updated-s10-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 10,liters|min|paco,low,VA (liters/min) PACO2 Chemosensitivity PaCO2 inversely related to alveolar ventilation (VA) 40 Alveolar Ventilation (VA) and Chemosensitivity 10
pulm-l8-wob-resp-pump-resp-failure-updated-s13-01,L8 WOB Resp Pump & Resp Failure updated.pptx,RESPIRATORY FAILURE,RESPIRATORY FAILURE,low,-------- Thoracic Cage Respiratory Muscle Nervous System HYPERCAPNIA Normal A—a gradient HYPOXEMIA Increased A—a gradient V / Q Mismatch Shunt Lung Failure Pump
pulm-l8-wob-resp-pump-resp-failure-updated-s34-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 34,PFT|restriction|chest|wall,low,Restriction: Chest Wall or Lung: Decreased Compliance Increased work of breathing (WOB) Increased elastic recoil Decrease in all Volumes Alveolar Reserve is Dec
pulm-l8-wob-resp-pump-resp-failure-updated-s35-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 35,COPD|increased|work|breathing,low,"Increased Work of Breathing (WOB) can Cause Respiratory Failure due to Respiratory Muscle Fatigue Normal Restrictive COPD Compared to normals, compliance curve "
pulm-l8-wob-resp-pump-resp-failure-updated-s36-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 36,normal|emphysema|work,low,Normal Emphysema Work of breathing is increased. Compensate by breathing at lower tidal volumes at faster rate Lung Transpulmonary Pressure (cm H2O) TV
pulm-l8-wob-resp-pump-resp-failure-updated-s39-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 39,COPD|normal|restrictive|copd,low,Normal Restrictive COPD 39 ABCF: NOTE that the resistive work during Expiration NO LONGER is within the stored elastic recoil energy OABCD. ODF is added work re
pulm-l8-wob-resp-pump-resp-failure-updated-s41-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 41,compliance|decreases|lung,low,Compliance Decreases as Lung Inflation Increases FRC RV TLC Hyperinflation Compliance decrease WOB increase Transpulmonary Pressure (cm H2O) Respiratory
pulm-l8-wob-resp-pump-resp-failure-updated-s42-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 42,respiratory|frequency|breaths,low,Respiratory Frequency (breaths/min) Dynamic Compliance & Airway Resistance Time Constants (TC) = resistance x compliance Normal = 5 x 100 = 500 TC = resistance 
pulm-l8-wob-resp-pump-resp-failure-updated-s43-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 43,work|breathing|obstructive,low,Work of Breathing in Obstructive Diseases (OAD) Bottom Panel Normal Restrictive OAD ABC: static inflation-deflation curve 43 OABCD: elastic work increased due t
pulm-l8-wob-resp-pump-resp-failure-updated-s44-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 44,obstructive|physiology|obstruction,low,Obstructive Physiology RV VC Obstruction Obstruction: Increase Airway Resistance Increase Respiratory Rate Decrease Flow: Decrease FEV-1 / FVC Prolonged expirat
pulm-l8-wob-resp-pump-resp-failure-updated-s45-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 45,hyperinflation|air|trapping,low,Hyperinflation = Air Trapping FRC Lung Volume Insp. Exp. Airway Obstruction with Progressive Dynamic Hyperinflation OAD attack During Obstructie airways disease
pulm-l8-wob-resp-pump-resp-failure-updated-s46-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 46,hyperinflation|increases|wob,low,"HYPERINFLATION INCREASES WOB, BUT SHORTENS DIAPHRAGM LENGTH Normal Flat, Shortened Diaphragm Obstructive Airways Diseases"
pulm-l8-wob-resp-pump-resp-failure-updated-s46-02,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 46,hyperinflation|increases|wob,low,"HYPERINFLATION INCREASES WOB, BUT SHORTENS DIAPHRAGM LENGTH Normal Flat, Shortened Diaphragm Obstructive Airways Diseases"
pulm-l8-wob-resp-pump-resp-failure-updated-s47-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 47,diaphragm|muscle|force,low,Diaphragm Muscle: Force - Length ___________ Hyperinflation: flattens & shortens diaphragm 47 Hyperinflation: mechanical disadvantage by reducing zone of apposi
pulm-l8-wob-resp-pump-resp-failure-updated-s48-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 48,asthma|emphysema|hyperinflation,low,Asthma Emphysema Hyperinflation Increase WOB due to increased resistance but also due to hyperinflation decreased compliance Lung Transpulmonary Pressure (cm H
pulm-l8-wob-resp-pump-resp-failure-updated-s49-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 49,asthma|emphysema|hyperinflation,low,Asthma Emphysema Hyperinflation Increase WOB due to increased resistance but also due to hyperinflation decreased compliance Lung Transpulmonary Pressure (cm H
pulm-l8-wob-resp-pump-resp-failure-updated-s51-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 51,work|breathing|obstructive,low,Work of Breathing in Obstructive Diseases Hyperinflation: PEEPi or Auto-PEEP No inspiratory flow until Inspiratory Pressure is negative relative to atmospheric 
pulm-l8-wob-resp-pump-resp-failure-updated-s52-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 52,hyperinflation|given|tidal,low,Hyperinflation: For any given tidal volume Greater distension pressure required at high volumes Over-distended balloons have decreased compliance Work of Breath
pulm-l8-wob-resp-pump-resp-failure-updated-s53-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 53,muscle|length|resting,low,Muscle Length (% resting length) FRC Force % max Hyperinflation  flattens & shortens diaphragm  decreased strength at the same time when demand increases TLC 
pulm-l8-wob-resp-pump-resp-failure-updated-s54-01,L8 WOB Resp Pump & Resp Failure updated.pptx,L8 WOB Resp Pump & Resp Failure updated Slide 54,normal|abnormal|diaphragm,low,Normal Abnormal 54 Diaphragm Muscle Decrease Strength after high dose systemic corticosteroid treatment or chronic malnutrition With long-term corticosteroid tr
pulm-l9-arterial-blood-gases-pulm-and-renal-combined-updated-v2-s06-01,L9 Arterial Blood Gases pulm and renal combined updated v2.pptx,L9 Arterial Blood Gases pulm and renal combined updated v2 Slide 6,ABG|easier|abg|interpretation,low,"For easier ABG interpretation, translate Henderson-Hasselbalch equation into: Stepwise Rules vs. Normogram AECOM & Step One Exams require rules; normogram not p"
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s05-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Case Study -1,Case Study -1|Case Study|1|COPD|SOB|presentation|caucasian|active,low,"Presentation: 59 Caucasian F, active heavy smoker (1ppd x 45yr), with PMH of COPD, p/w cough, chest discomfort and SOB. Initially treated as pneumonia but showe"
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s05-02,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Case Study -1,Case Study -1|Case Study|1|COPD|SOB|presentation|caucasian|active,low,"Presentation: 59 Caucasian F, active heavy smoker (1ppd x 45yr), with PMH of COPD, p/w cough, chest discomfort and SOB. Initially treated as pneumonia but showe"
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s06-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Case Study -1,Case Study -1|Case Study|1|what|likely|diagnosis,low,What is the most likely diagnosis? Small cell lung cancer EGFR-mutated lung adenocarcinoma EGFR wild type lung adenocarcinoma Pneumonia
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s06-02,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Case Study -1,Case Study -1|Case Study|1|what|likely|diagnosis,low,What is the most likely diagnosis? Small cell lung cancer EGFR-mutated lung adenocarcinoma EGFR wild type lung adenocarcinoma Pneumonia
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s07-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 7,risk|factors|nccn,low,"Risk Factors NCCN (National Comprehensive Cancer Network, Inc) guideline Version 1.2024; ASCO (American Society of Clinical Oncology) SEP 2023 Primary risk fact"
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s07-02,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 7,risk|factors|nccn,low,"Risk Factors NCCN (National Comprehensive Cancer Network, Inc) guideline Version 1.2024; ASCO (American Society of Clinical Oncology) SEP 2023 Primary risk fact"
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s11-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 11,paraneoplastic|syndromes|hpoa,low,Paraneoplastic syndromes HPOA: Hypertrophic pulmonary osteoarthropathy
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s13-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 13,characteristics|major|subtypes,low,Characteristics of Major Subtypes of Lung Cancer Adenocarcinoma (NSCLC) Small cell (SCLC)
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s13-02,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 13,characteristics|major|subtypes,low,Characteristics of Major Subtypes of Lung Cancer Adenocarcinoma (NSCLC) Small cell (SCLC)
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s13-03,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 13,characteristics|major|subtypes,low,Characteristics of Major Subtypes of Lung Cancer Adenocarcinoma (NSCLC) Small cell (SCLC)
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s14-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 14,nsclc|stages|tnm,low,"NSCLC stages (TNM) Staging of lung cancer follows the AJCC TNM staging system, which classifies the cancer based on the extent of the primary Tumor (Tis, T1-4),"
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s14-02,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 14,nsclc|stages|tnm,low,"NSCLC stages (TNM) Staging of lung cancer follows the AJCC TNM staging system, which classifies the cancer based on the extent of the primary Tumor (Tis, T1-4),"
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s15-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 15,diagnostic|staging|work-up,low,"Diagnostic/Staging Work-Up History and physical (including performance status, wt loss) CBC, chemistry profile Imaging tests: CT chest/abd(/pel) with contrast, "
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s17-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 17,histology|molecular|pd-l,low,Case 1 – histology/molecular/PD-L1 testing Underwent thoracentesis on 3/2/17: Left pleural fluid: Positive for malignant cells Immunohistochemical stains: favor
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s17-02,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 17,histology|molecular|pd-l,low,Case 1 – histology/molecular/PD-L1 testing Underwent thoracentesis on 3/2/17: Left pleural fluid: Positive for malignant cells Immunohistochemical stains: favor
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s18-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Case Study -1,Case Study -1|Case Study|1|what|likely|diagnosis,low,What is the most likely diagnosis? Small cell lung cancer EGFR-mutated lung adenocarcinoma EGFR wild type lung adenocarcinoma (Diagnosis: Stage IV lung adenocar
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s18-02,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Case Study -1,Case Study -1|Case Study|1|what|likely|diagnosis,low,What is the most likely diagnosis? Small cell lung cancer EGFR-mutated lung adenocarcinoma EGFR wild type lung adenocarcinoma (Diagnosis: Stage IV lung adenocar
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s19-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Case Study -1,Case Study -1|Case Study|1|what|likely|diagnosis,low,What is the most likely diagnosis? Small cell lung cancer EGFR-mutated lung adenocarcinoma EGFR wild type lung adenocarcinoma (Diagnosis: Stage IV lung adenocar
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s19-02,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Case Study -1,Case Study -1|Case Study|1|what|likely|diagnosis,low,What is the most likely diagnosis? Small cell lung cancer EGFR-mutated lung adenocarcinoma EGFR wild type lung adenocarcinoma (Diagnosis: Stage IV lung adenocar
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s22-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 22,goals|care|early,low,Goals of Care Early stages - Curative intent: Need local therapy (surgery or RT) Chemotherapy alone cannot cure lung cancer. Surgery (or RT) alone Surgery + neo
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s30-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 30,introduction|immunotherapy|pd-,low,"Introduction to immunotherapy: The PD-1/PD-L1 pathway Ohaegbulam KC et al: Trends Mol Med, 2015 Ribas, NEJM 2015 Inhibitory immune checkpoints, such as PD-1/PD-"
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s30-02,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 30,introduction|immunotherapy|pd-,low,"Introduction to immunotherapy: The PD-1/PD-L1 pathway Ohaegbulam KC et al: Trends Mol Med, 2015 Ribas, NEJM 2015 Inhibitory immune checkpoints, such as PD-1/PD-"
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s36-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 36,front|line|pembrolizumab,low,"Front Line Pembrolizumab vs Chemo for PD-L1–Positive (≥50%) NSCLC (KEYNOTE-024) The mPFS was 10.3 months (Pembro) vs 6.0 months (Chemo) (HR, 0.50, P<0.001) The "
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s36-02,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 36,front|line|pembrolizumab,low,"Front Line Pembrolizumab vs Chemo for PD-L1–Positive (≥50%) NSCLC (KEYNOTE-024) The mPFS was 10.3 months (Pembro) vs 6.0 months (Chemo) (HR, 0.50, P<0.001) The "
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s37-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 37,pd-l|positive|nsclc,low,"In PD-L1–Positive (≥50%) NSCLC, Pembrolizumab doubled median OS compared to chemotherapy! You don’t need to memorize regimens — please recognize the decision po"
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s39-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 39,keynote-|study|don,low,KEYNOTE-189 study You don’t need to memorize regimens — please recognize the decision points.
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s41-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 41,immune-related|adverse|events,low,Immune-related adverse events (irAEs) Immunotherapy can result in inflammation of any organ
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s43-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 43,molecularly-targeted|therapy|using,low,MOLECULARLY-TARGETED THERAPY: using molecular biology to improve therapeutic strategies
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s44-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 44,modified|clin|oncol,low,"Modified from Li T, et al. J Clin Oncol. 2013;31(8):1039-1049. Evolution of NSCLC: Subtyping from Histologic to Molecular Based"
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s47-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 47,treatment|egfr-mutated|nsclc,low,Treatment: EGFR-mutated NSCLC Key clinical trials: FLAURA: osimertinib improved OS vs earlier TKIs in advanced EGFR-mutant NSCLC. Sources: FLAURA OS (NEJM 2020)
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s48-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 48,treatment|egfr-mutated|nsclc,low,Treatment: EGFR-mutated NSCLC Key clinical trials: FLAURA: osimertinib improved OS vs earlier TKIs in advanced EGFR-mutant NSCLC. FLAURA2:osimertinib + platinum
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s49-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 49,fish|nature|aug,low,"FISH Nature, Aug 2, 2007 ALK Rearrangement in NSCLC Rearrangements in the ALK gene can lead to a fusion oncogene with transforming potential. For example, EML4-"
pulm-lung-cancer-therapy-einstein-02042026-wo-rd-s58-01,Lung Cancer Therapy - Einstein 02042026 - wo_rd.pptx,Lung Cancer Therapy - Einstein 02042026 - wo_rd Slide 58,take|home|messages,low,Take home Messages: Summary ★ High-yield Screen the right people with annual LDCT (USPSTF 50–80 + 20 pack-years + quit <15 years). Confirm diagnosis and stage c
pulm-medical-student-lung-cancer-2026-s03-01,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 3,jemal|cancer|clin,low,| 3 12/12/2023 Jemal Ca Cancer J Clin 2007 2023
pulm-medical-student-lung-cancer-2026-s14-01,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 14,,low,| 14 12/12/2023
pulm-medical-student-lung-cancer-2026-s16-01,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 16,,low,| 16 12/12/2023
pulm-medical-student-lung-cancer-2026-s25-01,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 25,delicate|alveolar|walls,low,| 25 12/12/2023 Delicate alveolar walls (type II pneumocytes ) Atypical Adenomatous Hyperplasia (AAH <=5mm) Adenocarcinoma in situ (AIS <=30mm) Localized prolif
pulm-medical-student-lung-cancer-2026-s25-02,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 25,delicate|alveolar|walls,low,| 25 12/12/2023 Delicate alveolar walls (type II pneumocytes ) Atypical Adenomatous Hyperplasia (AAH <=5mm) Adenocarcinoma in situ (AIS <=30mm) Localized prolif
pulm-medical-student-lung-cancer-2026-s25-03,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 25,delicate|alveolar|walls,low,| 25 12/12/2023 Delicate alveolar walls (type II pneumocytes ) Atypical Adenomatous Hyperplasia (AAH <=5mm) Adenocarcinoma in situ (AIS <=30mm) Localized prolif
pulm-medical-student-lung-cancer-2026-s35-01,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 35,ciliated|pseudostratified|columnar,low,| 35 12/12/2023 Ciliated Pseudostratified Columnar Epithelium Squamous metaplasia Squamous carcinoma in situ Invasive squamous carcinoma Progression of squamous
pulm-medical-student-lung-cancer-2026-s35-02,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 35,ciliated|pseudostratified|columnar,low,| 35 12/12/2023 Ciliated Pseudostratified Columnar Epithelium Squamous metaplasia Squamous carcinoma in situ Invasive squamous carcinoma Progression of squamous
pulm-medical-student-lung-cancer-2026-s35-03,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 35,ciliated|pseudostratified|columnar,low,| 35 12/12/2023 Ciliated Pseudostratified Columnar Epithelium Squamous metaplasia Squamous carcinoma in situ Invasive squamous carcinoma Progression of squamous
pulm-medical-student-lung-cancer-2026-s35-04,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 35,ciliated|pseudostratified|columnar,low,| 35 12/12/2023 Ciliated Pseudostratified Columnar Epithelium Squamous metaplasia Squamous carcinoma in situ Invasive squamous carcinoma Progression of squamous
pulm-medical-student-lung-cancer-2026-s37-01,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 37,keratin|pearl|orange-staining,low,"| 37 12/12/2023 Keratin pearl Orange-staining, keratinized cell with a prominent hyperchromatic nucleus"
pulm-medical-student-lung-cancer-2026-s37-02,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 37,keratin|pearl|orange-staining,low,"| 37 12/12/2023 Keratin pearl Orange-staining, keratinized cell with a prominent hyperchromatic nucleus"
pulm-medical-student-lung-cancer-2026-s37-03,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 37,keratin|pearl|orange-staining,low,"| 37 12/12/2023 Keratin pearl Orange-staining, keratinized cell with a prominent hyperchromatic nucleus"
pulm-medical-student-lung-cancer-2026-s45-01,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 45,ttf-|adenocarcinoma|squamous,low,| 45 12/12/2023 TTF-1 Adenocarcinoma Squamous cell carcinoma Small cell carcinoma Large cell carcinoma P40 Synaptophysin Chromogranin
pulm-medical-student-lung-cancer-2026-s45-02,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 45,ttf-|adenocarcinoma|squamous,low,| 45 12/12/2023 TTF-1 Adenocarcinoma Squamous cell carcinoma Small cell carcinoma Large cell carcinoma P40 Synaptophysin Chromogranin
pulm-medical-student-lung-cancer-2026-s45-03,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 45,ttf-|adenocarcinoma|squamous,low,| 45 12/12/2023 TTF-1 Adenocarcinoma Squamous cell carcinoma Small cell carcinoma Large cell carcinoma P40 Synaptophysin Chromogranin
pulm-medical-student-lung-cancer-2026-s48-01,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 48,,low,| 48 12/12/2023
pulm-medical-student-lung-cancer-2026-s52-01,Medical Student lung cancer 2026.pptx,PARANEOPLASTIC SYNDROMES,PARANEOPLASTIC SYNDROMES,low,| 52 12/12/2023
pulm-medical-student-lung-cancer-2026-s55-01,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 55,,low,| 55 12/12/2023
pulm-medical-student-lung-cancer-2026-s55-02,Medical Student lung cancer 2026.pptx,Medical Student lung cancer 2026 Slide 55,,low,| 55 12/12/2023
pulm-medical-student-lung-cancer-2026-s64-01,Medical Student lung cancer 2026.pptx,FDG-PETCT,FDG-PETCT|FDG|PETCT,low,"Non-Invasive FDG accumulates in metabolic cells Sensitivity ~72-95%, specificity ~83% False negatives Small < 8-10mm Slow growing/well differentiated tumors Fal"
pulm-oad-part-1-definitions-epidemiology-2026-s05-01,OAD Part 1 – Definitions & Epidemiology 2026 .pptx,OAD Part 1 – Definitions & Epidemiology 2026  Slide 5,COPD|asthma|copd|chronic,low,Asthma is Not COPD Chronic Bronchitis & Emphysema is COPD 5
pulm-oad-part-1-definitions-epidemiology-2026-s14-01,OAD Part 1 – Definitions & Epidemiology 2026 .pptx,OAD Part 1 – Definitions & Epidemiology 2026  Slide 14,,low,14
pulm-oad-part-1-definitions-epidemiology-2026-s17-01,OAD Part 1 – Definitions & Epidemiology 2026 .pptx,OAD Part 1 – Definitions & Epidemiology 2026  Slide 17,reid|index|normal,low,Reid Index <0.4 = Normal Reid Index bc/ad = mucous gland/bronchial wall thickness 17
pulm-oad-part-1-definitions-epidemiology-2026-s18-01,OAD Part 1 – Definitions & Epidemiology 2026 .pptx,OAD Part 1 – Definitions & Epidemiology 2026  Slide 18,medium|small|airways,low,medium & small airways 18 small airways Alveoli & small airways
pulm-oad-part-1-definitions-epidemiology-2026-s20-01,OAD Part 1 – Definitions & Epidemiology 2026 .pptx,OAD Part 1 – Definitions & Epidemiology 2026  Slide 20,components|secondary|lobule,low,Components of secondary lobule or acinus 20
pulm-oad-part-1-definitions-epidemiology-2026-s21-01,OAD Part 1 – Definitions & Epidemiology 2026 .pptx,OAD Part 1 – Definitions & Epidemiology 2026  Slide 21,starts|respiratory|bronchioles,low,Starts in Respiratory Bronchioles Starts in Alveolar Airspaces Centrilobular or Panlobular Emphysema 21
pulm-oad-part-1-definitions-epidemiology-2026-s25-01,OAD Part 1 – Definitions & Epidemiology 2026 .pptx,OAD Part 1 – Definitions & Epidemiology 2026  Slide 25,centrilobular|emphysema|bullae,low,Centrilobular Emphysema & Bullae in bilateral upper lobes 25 Bullae
pulm-oad-part-1-definitions-epidemiology-2026-s26-01,OAD Part 1 – Definitions & Epidemiology 2026 .pptx,OAD Part 1 – Definitions & Epidemiology 2026  Slide 26,panacinar|emphysema|bullae,low,Panacinar Emphysema & Bullae in bilateral lower lobes 26 Bullae
pulm-oad-part-1-definitions-epidemiology-2026-s28-01,OAD Part 1 – Definitions & Epidemiology 2026 .pptx,OAD Part 1 – Definitions & Epidemiology 2026  Slide 28,bronchiectasis,low,Bronchiectasis 28
pulm-oad-part-1-definitions-epidemiology-2026-s30-01,OAD Part 1 – Definitions & Epidemiology 2026 .pptx,OAD Part 1 – Definitions & Epidemiology 2026  Slide 30,,low,
pulm-oad-part-1-definitions-epidemiology-2026-s31-01,OAD Part 1 – Definitions & Epidemiology 2026 .pptx,OAD Part 1 – Definitions & Epidemiology 2026  Slide 31,,low,31
pulm-oad-part-1-definitions-epidemiology-2026-s35-01,OAD Part 1 – Definitions & Epidemiology 2026 .pptx,OAD Part 1 – Definitions & Epidemiology 2026  Slide 35,,low,
pulm-oad-part-1-definitions-epidemiology-2026-s39-01,OAD Part 1 – Definitions & Epidemiology 2026 .pptx,OAD Part 1 – Definitions & Epidemiology 2026  Slide 39,role|respiratory|tract,low,39 The Role of Respiratory Tract Infections in Asthma
pulm-oad-part-1-definitions-epidemiology-2026-s57-01,OAD Part 1 – Definitions & Epidemiology 2026 .pptx,OAD Part 1 – Definitions & Epidemiology 2026  Slide 57,,low,57
pulm-oad-part-2-clinical-characteristics-2026-s05-01,OAD part 2 clinical characteristics 2026.pptx,OAD part 2 clinical characteristics 2026 Slide 5,COPD|copd|pathogenesis|environmental,low,COPD PATHOGENESIS Environmental factors 5 Tobacco Smoke
pulm-oad-part-2-clinical-characteristics-2026-s06-01,OAD part 2 clinical characteristics 2026.pptx,OAD part 2 clinical characteristics 2026 Slide 6,,low,6
pulm-oad-part-2-clinical-characteristics-2026-s09-01,OAD part 2 clinical characteristics 2026.pptx,OAD part 2 clinical characteristics 2026 Slide 9,,low,9
pulm-oad-part-2-clinical-characteristics-2026-s12-01,OAD part 2 clinical characteristics 2026.pptx,OAD part 2 clinical characteristics 2026 Slide 12,blue|bloaters|hypoxia,low,"Blue bloaters, hypoxia Pink Puffer, Cachexia, No hypoxia 12"
pulm-oad-part-2-clinical-characteristics-2026-s13-01,OAD part 2 clinical characteristics 2026.pptx,OAD part 2 clinical characteristics 2026 Slide 13,COPD|copd|symptoms|cachexia,low,"13 COPD Symptoms COPD: Symptoms, Cachexia & Use of Accessory Muscles"
pulm-oad-part-2-clinical-characteristics-2026-s14-01,OAD part 2 clinical characteristics 2026.pptx,OAD part 2 clinical characteristics 2026 Slide 14,COPD|copd|hyperinflation|common,low,COPD  Hyperinflation Hyperinflation more common in Emphysema than Chronic Bronchitis Why? loss of elastic recoil 14
pulm-oad-part-2-clinical-characteristics-2026-s15-01,OAD part 2 clinical characteristics 2026.pptx,OAD part 2 clinical characteristics 2026 Slide 15,clubbing|hypoxemia|inflammation,low,"15 Clubbing from hypoxemia & inflammation With clubbing, proliferation of tissue under the nail plate causes this angle to increase to more than 160 degrees"
pulm-oad-part-2-clinical-characteristics-2026-s15-02,OAD part 2 clinical characteristics 2026.pptx,OAD part 2 clinical characteristics 2026 Slide 15,clubbing|hypoxemia|inflammation,low,"15 Clubbing from hypoxemia & inflammation With clubbing, proliferation of tissue under the nail plate causes this angle to increase to more than 160 degrees"
pulm-oad-part-2-clinical-characteristics-2026-s29-01,OAD part 2 clinical characteristics 2026.pptx,OAD part 2 clinical characteristics 2026 Slide 29,,low,29 ?
pulm-oad-part-2-clinical-characteristics-2026-s30-01,OAD part 2 clinical characteristics 2026.pptx,OAD part 2 clinical characteristics 2026 Slide 30,oad|phenotypes|impact,low,30 OAD Phenotypes: impact on severity and mortality
pulm-oad-part-2-clinical-characteristics-2026-s35-01,OAD part 2 clinical characteristics 2026.pptx,OAD part 2 clinical characteristics 2026 Slide 35,past|weeks|much,low,"In the past 4 weeks, how much of the time did your asthma keep you from getting as much done at work, school or at home? During the past 4 weeks, how often have"
pulm-oad-part-3-copd-asthma-treatment-2026-s05-01,OAD part 3 COPD & asthma treatment 2026.pptx,OAD part 3 COPD & asthma treatment 2026 Slide 5,tobacco|cessation|alters,low,Tobacco Cessation Alters Progression 5
pulm-oad-part-3-copd-asthma-treatment-2026-s07-01,OAD part 3 COPD & asthma treatment 2026.pptx,OAD part 3 COPD & asthma treatment 2026 Slide 7,oad|phenotypes|impact,low,7 OAD Phenotypes: impact on severity and mortality
pulm-oad-part-3-copd-asthma-treatment-2026-s11-01,OAD part 3 COPD & asthma treatment 2026.pptx,OAD part 3 COPD & asthma treatment 2026 Slide 11,inhaler|nebulizer,low,11 Inhaler vs. Nebulizer
pulm-oad-part-3-copd-asthma-treatment-2026-s13-01,OAD part 3 COPD & asthma treatment 2026.pptx,OAD part 3 COPD & asthma treatment 2026 Slide 13,SOB|COPD|improve|pulmonary|function,low,Improve pulmonary function/SOB/exercise performance Improve Quality of Life (QOL) For COPD 1st line therapy: Short-acting muscarinic antagonist (SAMA) = Anti-ch
pulm-oad-part-3-copd-asthma-treatment-2026-s14-01,OAD part 3 COPD & asthma treatment 2026.pptx,OAD part 3 COPD & asthma treatment 2026 Slide 14,COPD|inhaled|bronchodilators|anticholinergics,low,"INHALED BRONCHODILATORS: Anticholinergics (muscarinic antagonists) For COPD, results in greater FEV1 increase than Beta-2 agonists No tachycardia, no palpitatio"
pulm-oad-part-3-copd-asthma-treatment-2026-s15-01,OAD part 3 COPD & asthma treatment 2026.pptx,OAD part 3 COPD & asthma treatment 2026 Slide 15,,low,15
pulm-oad-part-3-copd-asthma-treatment-2026-s20-01,OAD part 3 COPD & asthma treatment 2026.pptx,OAD part 3 COPD & asthma treatment 2026 Slide 20,tiotropium|spiriva|long,low,Tiotropium (Spiriva) Long acting anticholinergic agent Acts at the Muscarinic Receptors 20
pulm-oad-part-3-copd-asthma-treatment-2026-s26-01,OAD part 3 COPD & asthma treatment 2026.pptx,OAD part 3 COPD & asthma treatment 2026 Slide 26,,low,26
pulm-oad-part-3-copd-asthma-treatment-2026-s31-01,OAD part 3 COPD & asthma treatment 2026.pptx,OXYGEN THERAPY,OXYGEN THERAPY|COPD,low,Definite survival benefit in severe COPD Improved QOL Increased exertional & cognitive abilities Should be considered for patients with: 1. 24hr/7 days in those
pulm-oad-part-3-copd-asthma-treatment-2026-s36-01,OAD part 3 COPD & asthma treatment 2026.pptx,OAD part 3 COPD & asthma treatment 2026 Slide 36,tracheostomy,low,tracheostomy 36
pulm-oad-part-3-copd-asthma-treatment-2026-s42-01,OAD part 3 COPD & asthma treatment 2026.pptx,OAD part 3 COPD & asthma treatment 2026 Slide 42,,low,42 ?
pulm-oad-part-3-copd-asthma-treatment-2026-s43-01,OAD part 3 COPD & asthma treatment 2026.pptx,OAD part 3 COPD & asthma treatment 2026 Slide 43,steroids|excellent|response,low,-- STEROIDS Excellent response -- STEROIDS Mild to Moderate response: acute Response to Basic Drug Therapies 43 SAMA LAMA Beta 2 agonist Beta agonist Beta 2 ago
pulm-oad-part-3-copd-asthma-treatment-2026-s44-01,OAD part 3 COPD & asthma treatment 2026.pptx,OAD part 3 COPD & asthma treatment 2026 Slide 44,,low,44
pulm-oad-part-3-copd-asthma-treatment-2026-s46-01,OAD part 3 COPD & asthma treatment 2026.pptx,OAD part 3 COPD & asthma treatment 2026 Slide 46,SOB|COPD|improve|pulmonary|function,low,Improve pulmonary function/SOB/exercise performance Improve Quality of Life (QOL) For Asthma it is the opposite of COPD 1st line therapy: Short-acting beta-agon
pulm-oad-part-3-copd-asthma-treatment-2026-s47-01,OAD part 3 COPD & asthma treatment 2026.pptx,OAD part 3 COPD & asthma treatment 2026 Slide 47,COPD|inhaled|bronchodilators|beta-,low,"INHALED BRONCHODILATORS: Beta-2 Agonists more effective bronchodilator in Asthma Beta-2 vs. Beta-1: More selective to airway receptors Less tachycardia, less tr"
pulm-oad-part-4-asthma-treatment-continued-2026-s05-01,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 5,past|weeks|much,low,"In the past 4 weeks, how much of the time did your asthma keep you from getting as much done at work, school or at home? During the past 4 weeks, how often have"
pulm-oad-part-4-asthma-treatment-continued-2026-s22-01,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 22,,low,22
pulm-oad-part-4-asthma-treatment-continued-2026-s25-01,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 25,,low,
pulm-oad-part-4-asthma-treatment-continued-2026-s26-01,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 26,whats|new|use,low,WHATS NEW = Use of low dose inhaled corticosteroid + long-acting beta-agonist [formoterol] instead of rescue short-acting beta-agonist
pulm-oad-part-4-asthma-treatment-continued-2026-s27-01,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 27,,low,
pulm-oad-part-4-asthma-treatment-continued-2026-s28-01,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 28,,low,
pulm-oad-part-4-asthma-treatment-continued-2026-s29-01,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 29,,low,
pulm-oad-part-4-asthma-treatment-continued-2026-s31-01,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 31,,low,
pulm-oad-part-4-asthma-treatment-continued-2026-s32-01,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 32,biologics|treatment,low,32 Biologics Biologics Treatment
pulm-oad-part-4-asthma-treatment-continued-2026-s40-01,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 40,,low,40
pulm-oad-part-4-asthma-treatment-continued-2026-s41-01,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 41,response|irritant|induced,low,"41 TH1 Response: irritant induced, neutrophilic TH2 Response: allergic, eosinophilic"
pulm-oad-part-4-asthma-treatment-continued-2026-s42-01,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 42,tezepelumab|blue|box,low,42 Tezepelumab Blue box medications are commercially available & very expensive
pulm-oad-part-4-asthma-treatment-continued-2026-s43-01,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 43,omalizumab|zolair|step,low,Omalizumab (Zolair) Step 4 & above with elevated IGE level 43
pulm-oad-part-4-asthma-treatment-continued-2026-s43-02,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 43,omalizumab|zolair|step,low,Omalizumab (Zolair) Step 4 & above with elevated IGE level 43
pulm-oad-part-4-asthma-treatment-continued-2026-s46-01,OAD part 4 Asthma treatment continued 2026.pptx,OAD part 4 Asthma treatment continued 2026 Slide 46,,low,
pulm-patterns-of-interstitial-lung-diseases-2025-s09-01,Patterns of Interstitial Lung Diseases 2025.pptx,Patterns of Interstitial Lung Diseases 2025 Slide 9,hrct|ipf|dilated,low,HRCT for IPF: dilated airspaces in subpleural location
pulm-patterns-of-interstitial-lung-diseases-2025-s10-01,Patterns of Interstitial Lung Diseases 2025.pptx,Patterns of Interstitial Lung Diseases 2025 Slide 10,macroscopic|appearance|subpleural,low,Macroscopic Appearance Subpleural fibrosis with dilated air spaces (honeycombing) Involvement of lower lobes initially in IPF
pulm-patterns-of-interstitial-lung-diseases-2025-s14-01,Patterns of Interstitial Lung Diseases 2025.pptx,Patterns of Interstitial Lung Diseases 2025 Slide 14,subpleural|fibrosis,low,Subpleural fibrosis
pulm-patterns-of-interstitial-lung-diseases-2025-s16-01,Patterns of Interstitial Lung Diseases 2025.pptx,Patterns of Interstitial Lung Diseases 2025 Slide 16,fibroblastic|foci,low,Fibroblastic foci
pulm-patterns-of-interstitial-lung-diseases-2025-s29-01,Patterns of Interstitial Lung Diseases 2025.pptx,Patterns of Interstitial Lung Diseases 2025 Slide 29,,low,
pulm-patterns-of-interstitial-lung-diseases-2025-s34-01,Patterns of Interstitial Lung Diseases 2025.pptx,DIP,DIP,low,
pulm-patterns-of-interstitial-lung-diseases-2025-s75-01,Patterns of Interstitial Lung Diseases 2025.pptx,Patterns of Interstitial Lung Diseases 2025 Slide 75,,low,
pulm-patterns-of-interstitial-lung-diseases-2025-s76-01,Patterns of Interstitial Lung Diseases 2025.pptx,Patterns of Interstitial Lung Diseases 2025 Slide 76,,low,
pulm-patterns-of-interstitial-lung-diseases-2025-s77-01,Patterns of Interstitial Lung Diseases 2025.pptx,Patterns of Interstitial Lung Diseases 2025 Slide 77,,low,
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s02-01,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 2,,low,
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s02-02,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 2,,low,
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s07-01,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 7,conducting|bulk|flow,low,Conducting (bulk flow) Transitional & Respiratory (diffusion)
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s08-01,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 8,gradual|flattening|move,low,Gradual flattening as move distally toward alveoli Clara cells are secretory non-ciliated bronchiolar epithelial cells www.mmi.mcgill.ca/.../images/eidelman-12n
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s13-01,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 13,tracheoesophageal|fistulae|esophageal,low,Tracheoesophageal Fistulae Esophageal atresia Tracheoesophageal fistula Failure of separation of respiratory and GI tracts early in embryogenesis Treatment is s
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s15-01,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 15,TB|kinane|engl|med,low,Kinane TB et al. N Engl J Med2024;391:1838-1846 CPAM Type 1 is most common Bronchogenic cysts Congenital lobar overinflation Bronchopulmonary sequestration
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s15-02,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 15,TB|kinane|engl|med,low,Kinane TB et al. N Engl J Med2024;391:1838-1846 CPAM Type 1 is most common Bronchogenic cysts Congenital lobar overinflation Bronchopulmonary sequestration
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s16-01,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 16,congenital|pulmonary|airway,low,Congenital Pulmonary Airway Malformation (CPAM) CPAM
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s16-02,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 16,congenital|pulmonary|airway,low,Congenital Pulmonary Airway Malformation (CPAM) CPAM
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s17-01,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 17,,low,
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s17-02,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 17,,low,
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s18-01,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 18,TB|bronchopulmonary|sequestration|kinane,low,Bronchopulmonary Sequestration Kinane TB et al. N Engl J Med2024;391:1838-1846
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s18-02,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 18,TB|bronchopulmonary|sequestration|kinane,low,Bronchopulmonary Sequestration Kinane TB et al. N Engl J Med2024;391:1838-1846
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s18-03,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 18,TB|bronchopulmonary|sequestration|kinane,low,Bronchopulmonary Sequestration Kinane TB et al. N Engl J Med2024;391:1838-1846
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s18-04,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 18,TB|bronchopulmonary|sequestration|kinane,low,Bronchopulmonary Sequestration Kinane TB et al. N Engl J Med2024;391:1838-1846
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s22-01,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 22,pulmonary|surfactant|synthesis,low,"Pulmonary Surfactant Synthesis - 18 wks, Secretion - 28 wks Lipid (90%) Most phospholipid 70-80% dipalmitoyl phosphatidylcholine Mature lung More phosphatidyl g"
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s22-02,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 22,pulmonary|surfactant|synthesis,low,"Pulmonary Surfactant Synthesis - 18 wks, Secretion - 28 wks Lipid (90%) Most phospholipid 70-80% dipalmitoyl phosphatidylcholine Mature lung More phosphatidyl g"
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s22-03,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 22,pulmonary|surfactant|synthesis,low,"Pulmonary Surfactant Synthesis - 18 wks, Secretion - 28 wks Lipid (90%) Most phospholipid 70-80% dipalmitoyl phosphatidylcholine Mature lung More phosphatidyl g"
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s22-04,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 22,pulmonary|surfactant|synthesis,low,"Pulmonary Surfactant Synthesis - 18 wks, Secretion - 28 wks Lipid (90%) Most phospholipid 70-80% dipalmitoyl phosphatidylcholine Mature lung More phosphatidyl g"
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s22-05,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 22,pulmonary|surfactant|synthesis,low,"Pulmonary Surfactant Synthesis - 18 wks, Secretion - 28 wks Lipid (90%) Most phospholipid 70-80% dipalmitoyl phosphatidylcholine Mature lung More phosphatidyl g"
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s40-01,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 40,normal|larynx|courtesy,low,"The Normal Larynx Image is courtesy of Sanjay Parikh, MD, The Children’s Hospital at Montefiore Reproduced with permission. Epiglottis Vocal cords Esophagus Ary"
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s42-01,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 42,laryngotracheobronchitis|croup|treatments,low,Laryngotracheobronchitis (Croup) Treatments 1. Racemic epinephrine 2. Dexamethasone 3. Cool mist?
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s58-01,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 58,nejm|combination|treatment,low,NEJM 2021;385(9):815-825 Combination treatment with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators tezacaftor (VX-661) and Ivacaftor 
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s58-02,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 58,nejm|combination|treatment,low,NEJM 2021;385(9):815-825 Combination treatment with the cystic fibrosis transmembrane conductance regulator (CFTR) modulators tezacaftor (VX-661) and Ivacaftor 
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s59-01,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 59,,low,
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s59-02,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 59,,low,
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s60-01,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 60,,low,
pulm-pediatric-lung-disease-lecture-2026-final-1-1-s60-02,Pediatric Lung Disease Lecture 2026 _Final-1 (1).pptx,Pediatric Lung Disease Lecture 2026 _Final-1 (1) Slide 60,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s01-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 1,pulmonary|physiology|large,low,"PULMONARY PHYSIOLOGY Large Group Discussion Workshop PART ONE Topics: Resistance, Compliance, Alveolar Ventilation, Diffusion & Gas Transport Dr. David Prezant "
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s07-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 7,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s08-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 8,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s11-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 11,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s12-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 12,frc|tlc|transpulmonary,low,FRC + TV RV TLC Transpulmonary Pressure (cm H2O) Respiratory Normal 700 ml; 3 cm C = 233 ml/cm Compliance = ∆V/ ∆ P 12 Compliance = Volume change / Pressure cha
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s13-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 13,compliance|decreases|hyperinflation,low,Compliance Decreases with Hyperinflation RV TLC Transpulmonary Pressure (cm H2O) Respiratory 700 ml; 3 cm C = 233 Hyperinflated 700 ml; 10 cm C = 70 FRC + TV Co
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s14-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 14,normals|asthmatics|respiratory,low,Normals Asthmatics Respiratory Frequency (breaths/min) Dynamic Compliance & Airway Resistance Time Constant = R x C Normal = 5x100 = 500 Asthma=40 x100=4000 Hyp
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s16-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 16,normal|peco|phase,low,Normal PECO2 = 25 - 37 mm Hg phase phase phase CO2 AS CO2 CO2 CO2 CO2
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s17-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 17,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s18-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 18,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s23-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 23,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s26-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 26,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s31-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 31,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s34-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 34,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s37-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 37,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s40-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 40,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s41-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 41,normal|adequate|time,low,"Normal: Adequate time for diffusion at rest & exercise Abnormal: Only if severe lung disease. With moderate disease, only if blood flow is rapid, thereby decrea"
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s43-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 43,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s45-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 45,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s56-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 56,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s59-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 59,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s62-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 62,wasted|ventilation|perfused,low,s Wasted Ventilation Under Perfused Ideal Matched V/Q IDEAL SHUNT DEAD SPACE V/Q=OO V/Q=O V/Q=1 PAO2 = 100 mmHg PACO2 = 40 mmHg PAO2 = 150 mmHg PACO2 = 0 mmHg P
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s63-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 63,ventilation|perfusion|ideal,low,Ventilation / Perfusion: IDEAL VS. DISEASE To Alveoli NOT Ventilated Normal Perfusion is “wasted” Venous Admixture s Wasted Ventilation Under Perfused Ideal V/Q
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s64-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 64,increases|poorly|ventilated,low,Increases in poorly ventilated lung with preserved perfusion: PaCO2 rises PaO2 falls PaO2 Increasing amount of Poorly ventilated lung Amount of poorly ventilate
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s65-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 65,increases|poorly|ventilated,low,Increases in poorly ventilated lung with preserved perfusion: PaCO2 rises PaO2 falls PaO2 Increasing amount of Poorly ventilated lung Amount of poorly ventilate
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s67-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 67,diseases|effect|ventilation,low,"Most Diseases effect ventilation more than perfusion leading to: Increase Low V/Q alveoli: PCO2 rises, PO2 falls In response, brain signals for VA to increase r"
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s69-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 69,dissolved|total|oxyhemoglobin,low,Dissolved O2 Total O2 Oxyhemoglobin O2 100 75 50 25 Hb Sat % PO2 mmHg 100 O2 Content = dissolved + saturated O2 dissolved is minimal HbO2 sat or O2 bound is cri
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s71-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 71,content|saturated|dissolved,low,71 O2 content = saturated + dissolved Content = O2 saturated + O2 dissolved Normal Hemoglobin = 15 g Hb / 100 ml blood (O2 sat x 1.34 ml O2/g Hb x 15g Hb) + (0.
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s72-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 72,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s73-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 73,sat|content|blood,low,"For PO2 of 110 (O2 sat = 100%) O2 content = (1 x 1.34 x 15) + (.003 x 110) = 20.1 + 0.33 = 20.43 ml O2 / 100 ml blood O2 Content for PO2 = 110, or 90 or 130 mmH"
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s74-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 74,pco|capillary|equilibrium,low,PcO2 = P capillary O2 in equilibrium with PAO2 Assume Equal perfusion to Each of 3 Areas O2 content = [(20.1+0.33) + (19.09+0.27) + (20.1+0.39)] / 3 = O2 conten
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s76-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 76,pulmonary|physiology|thanks,low,PULMONARY PHYSIOLOGY Thanks for your attention to SEE YOU AT WORKSHOP PART TWO
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s77-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 77,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s78-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 78,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s79-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 79,,low,
pulm-pulmonary-physiology-workshop-1-edited-poll-everywhere-2025-final-v5-multiple-choice-s80-01,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice).pptx,Pulmonary Physiology Workshop 1 edited poll everywhere-2025 (final v5-multiple choice) Slide 80,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s01-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,PULMONARY PHYSIOLOGY,PULMONARY PHYSIOLOGY|ABG,low,"Large Group Discussion WORKSHOP PART TWO Topics: Lectures covered: Arterial Blood Gases (ABG), A-a Gradient, V/Q Mismatch, Shunt Fraction, & Respiratory Failure"
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s10-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 10,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s12-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 12,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s17-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 17,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s19-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 19,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s24-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 24,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s28-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 28,reality|extremes|ventilated,low,V/Q Reality and Extremes Under Ventilated Wasted Perfusion Venous Admixture s Wasted Ventilation Under Perfused V/Q slightly <1 Reality – small shunt SHUNT DEA
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s29-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 29,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s32-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 32,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s34-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 34,increases|total|mismatch,low,Increases in total V/Q mismatch For most diseases increase in total V/Q mismatch is more low than high V/Q PaCO2 rises PaO2 falls PaO2 A lot of Mismatch V/Q=1 N
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s35-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 35,increases|total|mismatch,low,Increases in total V/Q mismatch For most diseases increase in total V/Q mismatch is more low than high V/Q PaCO2 rises PaO2 falls PaO2 A lot of Mismatch V/Q=1 N
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s37-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 37,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s38-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 38,sat|content|blood,low,"For PO2 of 110 (O2 sat = 100%) O2 content = (1 x 1.34 x 15) + (.003 x 110) = 20.1 + 0.33 = 20.43 ml O2 / 100 ml blood O2 Content for PO2 = 110, or 90 or 130 mmH"
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s39-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 39,pco|capillary|equilibrium,low,PcO2 = P capillary O2 in equilibrium with PAO2 Assume Equal perfusion to Each of 3 Areas O2 content = [(20.1+0.33) + (19.09+0.27) + (20.1+0.39)] / 3 = O2 conten
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s40-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 40,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s41-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 41,fio|pao|high,low,FIO2 PaO2 High V/Q 10 1.0 0.01 0.001 For a given FIO2: 10 x increase V/Q (ex. 1 to 10) minor increase PaO2 & O2 content Why? Because HbO2 already at max saturat
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s42-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 42,low|units|hbo,low,"But in low V/Q units, HbO2 sat is NOT 100% (ex. 0.1 vs 1) major decrease in O2 content which can be normalized with supplemental O2 100% FIO2 eliminates hypoxia"
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s44-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 44,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s45-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 45,pao|sat|content,low,"For PaO2 of 673 (O2 sat = 100%) O2 content = (1x1.34x15) + (.003 x 673) = 20.1 + 2.02 = 22.12 ml O2 / 100 ml blood O2 Content for PO2 = 673, 653 and 693 For PaO"
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s46-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 46,right|heart|left,low,Right Heart Left Heart PaO2 = 40 PaCO2 = 46 PAO2 = 673; PACO2 = 40 PAO2 = 653; PACO2 = 60 1/3 Q -> Low V/Q 1/3 Q-> High V/Q PAO2 =693; PACO2 = 20 All of the abo
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s47-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 47,right|heart|left,low,Right Heart Left Heart PaO2 = 40 PaCO2 = 46 R=1.0 PAO2 = 673; PACO2 = 40 PAO2 = 670; PACO2 = 43 PAO2 = 40; PACO2 = 46 Decreased V/Q Shunt V/Q=0 Assumes Equal pe
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s49-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 49,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s60-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 60,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s64-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 64,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s66-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 66,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s69-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 69,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s70-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 70,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s74-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 74,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s78-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 78,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s80-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 80,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s82-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP   Slide 82,,low,
pulm-pulmonary-physiology-workshop-2-edited-poll-everywhere-2026-v2-dp-s85-01,Pulmonary Physiology Workshop 2 edited poll everywhere-2026 v2 DP  .pptx,PULMONARY PHYSIOLOGY,PULMONARY PHYSIOLOGY,low,Thanks for your attention and when in doubt just Keep Breathing!
pulm-sleep-disordered-breathing-2026-2-s05-01,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 5,,low,
pulm-sleep-disordered-breathing-2026-2-s09-01,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 9,,low,
pulm-sleep-disordered-breathing-2026-2-s09-02,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 9,,low,
pulm-sleep-disordered-breathing-2026-2-s10-01,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 10,,low,
pulm-sleep-disordered-breathing-2026-2-s10-02,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 10,,low,
pulm-sleep-disordered-breathing-2026-2-s11-01,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 11,,low,
pulm-sleep-disordered-breathing-2026-2-s16-01,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 16,upstream|critical|pressure,low,Ve = P upstream - P critical pressure/ Resistance Starling Resistor Model
pulm-sleep-disordered-breathing-2026-2-s27-01,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 27,,low,
pulm-sleep-disordered-breathing-2026-2-s28-01,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 28,,low,
pulm-sleep-disordered-breathing-2026-2-s31-01,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 31,marin|lancet|sleep,low,Marin Lancet 2005; 365: 1046-1053 Sleep Disordered Breathing
pulm-sleep-disordered-breathing-2026-2-s31-02,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 31,marin|lancet|sleep,low,Marin Lancet 2005; 365: 1046-1053 Sleep Disordered Breathing
pulm-sleep-disordered-breathing-2026-2-s33-01,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 33,diagnosis|overnight|polysomnography,low,Diagnosis Overnight polysomnography Attenuated sleep studies – Home sleep tests Sleep Disordered Breathing
pulm-sleep-disordered-breathing-2026-2-s35-01,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 35,upstream|critical|pressure,low,Ve = P upstream -P critical pressure/ Resistance Sleep Disordered Breathing
pulm-sleep-disordered-breathing-2026-2-s37-01,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 37,OSA|kohler|thorax|osa,low,Kohler M Thorax 2010; 65: 829 OSA Severity To Predict CPAP USE Sleep Disordered Breathing
pulm-sleep-disordered-breathing-2026-2-s41-01,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 41,marin|lancet|sleep,low,Marin Lancet 2005; 365: 1046-1053 Sleep Disordered Breathing
pulm-sleep-disordered-breathing-2026-2-s41-02,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 41,marin|lancet|sleep,low,Marin Lancet 2005; 365: 1046-1053 Sleep Disordered Breathing
pulm-sleep-disordered-breathing-2026-2-s45-01,Sleep Disordered Breathing 2026-2.pptx,Sleep Disordered Breathing 2026-2 Slide 45,OSA|non-concurrent|cohort|study,low,Non-concurrent cohort study Cardiovascular mortality; severe OSA 208 Controls 570 Severe OSA; 177 CPAP; 72 OA; 212 Untreated Median follow-up time = 6.6 years S
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s01-01,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 1,review|exam|lung,low,"Review Session Exam 2 : Lung Cancer includes: Epidemiology, Screening, Diagnosis, Cell Types, Treatment and Tobacco Cessation Drs Rivkah Darabaner & David Preza"
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s01-02,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 1,review|exam|lung,low,"Review Session Exam 2 : Lung Cancer includes: Epidemiology, Screening, Diagnosis, Cell Types, Treatment and Tobacco Cessation Drs Rivkah Darabaner & David Preza"
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s03-01,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 3,jemal|cancer|clin,low,| 3 12/12/2023 Jemal Ca Cancer J Clin 2007 2023 The leading cause of cancer death in the US. Only 21% of lung cancer patients are alive 5 years or more after di
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s10-01,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 10,diagnostic|workup|lung,low,| 10 12/12/2023 Diagnostic workup for a lung nodule
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s21-01,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 21,keratin|pearl|orange-staining,low,"| 21 12/12/2023 Keratin pearl Orange-staining, keratinized cell with a prominent hyperchromatic nucleus Squamous cell carcinoma"
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s21-02,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 21,keratin|pearl|orange-staining,low,"| 21 12/12/2023 Keratin pearl Orange-staining, keratinized cell with a prominent hyperchromatic nucleus Squamous cell carcinoma"
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s32-01,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 32,adrenal|brain|liver,low,adrenal brain liver bone Mets:
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s32-02,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 32,adrenal|brain|liver,low,adrenal brain liver bone Mets:
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s32-03,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 32,adrenal|brain|liver,low,adrenal brain liver bone Mets:
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s32-04,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 32,adrenal|brain|liver,low,adrenal brain liver bone Mets:
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s34-01,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 34,nsclc|stages|tnm,low,"NSCLC stages (TNM) Staging of lung cancer follows the AJCC TNM staging system, which classifies the cancer based on the extent of the primary Tumor (Tis, T1-4),"
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s36-01,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,PET CT,PET CT|TB,low,"Non-Invasive PET (Fructose DG) accumulates in metabolic cells Uptake of radiolabeled sugar – if hypermetabolic Sensitivity ~72-95%, specificity ~83% False negat"
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s39-01,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 39,stage|adenopathy|mets,low,"Stage IB: T2 = >3cm, N0 = no adenopathy M0 = no mets NSCLC Staging"
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s45-01,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 45,diagnostic|algorithm|advanced,low,Diagnostic Algorithm for advanced NSCLC NCCN guideline Version 1.2023 Most common mutations in adenocarcinoma: Unknown EGFR KRAS ALK Most common mutations in sq
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s46-01,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 46,immunotherapy|pd-|pd-l,low,"Immunotherapy: The PD-1/PD-L1 pathway Ohaegbulam KC et al: Trends Mol Med, 2015 Ribas, NEJM 2015 Inhibitory immune checkpoints, such as PD-1/PD-L1, are part of "
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s46-02,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,review lecture LUNG CANCER with case conf images updated-2025 (1) Slide 46,immunotherapy|pd-|pd-l,low,"Immunotherapy: The PD-1/PD-L1 pathway Ohaegbulam KC et al: Trends Mol Med, 2015 Ribas, NEJM 2015 Inhibitory immune checkpoints, such as PD-1/PD-L1, are part of "
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s58-01,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,MESOTHELIOMA,MESOTHELIOMA,low,"Asbestos exposure + Tobacco smoke synergistic (50-100x increase) in lung cancer Mesothelioma only related to asbestos exposure In contrast to lung cancers, toba"
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s59-01,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,MESOTHELIOMA,MESOTHELIOMA,low,"| 59 Asbestos fibers Golden brown, beaded rods, coated with iron-containing proteinaceous material. electron micrograph Psammoma bodies Anthracotic pigments Fer"
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s59-02,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,MESOTHELIOMA,MESOTHELIOMA,low,"| 59 Asbestos fibers Golden brown, beaded rods, coated with iron-containing proteinaceous material. electron micrograph Psammoma bodies Anthracotic pigments Fer"
pulm-review-lecture-lung-cancer-with-case-conf-images-updated-2025-1-s59-03,review lecture LUNG CANCER with case conf images updated-2025 (1).pptx,MESOTHELIOMA,MESOTHELIOMA,low,"| 59 Asbestos fibers Golden brown, beaded rods, coated with iron-containing proteinaceous material. electron micrograph Psammoma bodies Anthracotic pigments Fer"
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s01-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 1,drs|rivkah|darabaner,low,Drs Rivkah Darabaner & David Prezant Co-Directors Pulmonary & Critical Care Medicine Course Exam 2 Review Session Part 1 – obstructive airways diseases
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s01-02,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 1,drs|rivkah|darabaner,low,Drs Rivkah Darabaner & David Prezant Co-Directors Pulmonary & Critical Care Medicine Course Exam 2 Review Session Part 1 – obstructive airways diseases
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s08-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 8,,low,8
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s09-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 9,asthma|epithelium|smooth,low,Asthma - Image 5 & 6 epithelium Smooth muscle eosinophils
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s09-02,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 9,asthma|epithelium|smooth,low,Asthma - Image 5 & 6 epithelium Smooth muscle eosinophils
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s10-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 10,risk|factor|role,low,10 Risk Factor: Role of Respiratory Tract Infections in Asthma
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s25-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 25,,low,
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s26-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 26,whats|new|use,low,WHATS NEW = Use of low dose inhaled corticosteroid + long-acting beta-agonist [formoterol] instead of rescue short-acting beta-agonist
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s27-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 27,,low,
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s29-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 29,,low,29
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s32-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 32,tezepelumab|blue|box,low,32 Tezepelumab Blue box medications are commercially available & very expensive Xolair Dupixent Texspire Nucala Fasenra
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s42-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 42,compliance|decreases|lung,low,Compliance Decreases as Lung Inflation Increases FRC RV TLC Compliance = V/P Transpulmonary Pressure (cm H2O) Respiratory 700 ml; 8 cm C = 88 700 ml; 15 cm C = 
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s43-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 43,normals|asthmatics|respiratory,low,Normals Asthmatics Respiratory Frequency (breaths/min) Increasing Minute Ventilation Rapid Rate Decreases Dynamic Compliance
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s44-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 44,lung|volume|increases,low,"Lung Volume Increases ---- FRC TLC RV Alveolar Hyperinflation: Decreases gas exchange by increasing PVR, V/Q mismatch & VD/VT"
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s46-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 46,hyperinflation|frc|approaches,low,"Hyperinflation, FRC approaches TLC Compliance Decreases Diaphragm Length & Force Decreased Curved Diaphragm Flat Shortened Diaphragm Normal Obstructive Diseases"
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s46-02,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 46,hyperinflation|frc|approaches,low,"Hyperinflation, FRC approaches TLC Compliance Decreases Diaphragm Length & Force Decreased Curved Diaphragm Flat Shortened Diaphragm Normal Obstructive Diseases"
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s49-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 49,chest|radiograph|showing,low,Chest radiograph showing large left pneumothorax with loss of lung markings in the upper chest
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s52-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 52,normal|obstructive|work,low,Normal Obstructive WORK of BREATHING: Mechanical Ventilation Resistance R = (Peak – Static Pressure) / Flow rate Compliance C = Tidal Volume / Static Pressure A
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s56-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 56,COPD|copd|pathogenesis|environmental,low,COPD PATHOGENESIS Environmental factors 56 Tobacco Smoke
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s58-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 58,COPD|asthma|copd|chronic,low,Asthma is Not COPD Chronic Bronchitis & Emphysema is COPD 58
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s60-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 60,,low,60 ?
pulm-review-lecture-intro-and-obstructive-airways-dx-updated-2025-s63-01,review lecture intro and obstructive airways dx_updated 2025.pptx,review lecture intro and obstructive airways dx_updated 2025 Slide 63,chronic|bronchitis,low,Chronic Bronchitis Image 8
